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S U M M A R Y  ;; ,
In recent years much interest has been generated in 
the concept of tumour agents or "signal factors" (Toporek, 
1975) affecting host metabolic processes. It has been 
shorn that tumour growth markedly alters the metabolism of 
and induces biochemical changes in various tissues and 
organs of the host (Theologides, 1972). These effects 
occur at sites remote from the site of tumour growth, 
therefore the possibility of the secretion of chemical 
modulators by the tumour cells must be considered.
Previous work (Caiman and McAllister, 1975(a),
1975(b)) using a variety of experimental tumours has 
demonstrated metabolic abnormalities in the livers of 
tumour-bearing micco Of the tumour systems studied the 
TLX-5 lymphoma is of particular interest, since a cell-free 
ascitic fluid preparation of this tumour, when injected 
into normal mice, will produce these same liver metabolic 
changes without subsequent tumour growth occurring 
(McAllister, Soukop and Caiman, 1976). The most 
significant of these liver metabolite changes produced were 
an increase in citrate content and a decrease in 
COenzyme-A levels.
It was postulated, therefore, that a factor or factors 
present in this tumour cell-free preparation was respon­
sible for producing these metabolic abnormalities, and the 
work described in this thesis demonstrates the presence 
of a factor in the ascitic fluid and serum of tumour- 
bearing mice responsible for increasing hepatic citrate 
levels. This work also demonstrates the presence of
other factors in ascitic fluid responsible for spleen 
hypertrophy, thymic atrophy and increases in epididymal 
fat pad weight.
Since ascitic fluid from mice bearing TLX-5 lymphoma 
contains a multiplicity of host and tumour derived factors 
which may be involved in producing the observed metabolic 
changes, it was necessary to determine whether the factor 
or factors involved in increasing hepatic citrate levels 
was of host or tumour origin. It was shovm likely to be 
of tumour origin, since it was present in the cell-free 
growth medium of TLX-5 cells gro\,vn in vitro.
This biologically active factor was also shov/n to be 
non-dialysable, heat labile and protein in nature, since 
treatment of cell-free ascitic fluid with trypsin destroyed 
its biological activityo
High speed centrifugation of the cell-free ascitic 
fluid preparation did not affect its biological activity, 
and resulted in considerable purification of the 
preparation in terms of protein content, as well as removing 
any virus particles present. The problem of viral 
contamination of TLX-5 Ipmiphoma was investigated, and 
in vivo grown tumour cells were shovn to be contaminated 
with a virus. The factor involved in increasing hepatic 
citrate levels is, however, unlikely to be viral in nature 
since it' is present in virus free ascitic fluid 
preparations, and in a preparation of in vitro grown 
tumour cells which have been shown to be free of virun.
The viral contaminant of the in vivo grovn tumour 
cells may be the Riley virus or lactate dehydrogenase
virus (LDV) since it has been shov/n to be a widespread 
contaminant of murine tumours. Electron microscope 
examination of the in vivo grown cells revealed a virus 
particle with a similar size and shape to LDV, but this 
particle could not be detected in the in vitro grown cells.
Injection of the in vivo grown cells into normal mice 
did produce an elevation of serum lactate dehydrogenase 
activity in these animals, which is a characteristic 
effect of LDV. Injection of virus-free ascitic fluid (SN2) 
into normal animals also produced this effect, therefore 
it would appear that a factor or factors present in the 
tumour cell preparation and in the virus-free preparation 
are responsible for producing this effect.
Gel filtration and gel. electrophoresis experiments 
using, SN2 indicate that the factor present in SN2 ' ^ 
responsible for increasing hepatic citrate levels has a 
molecular weight between 6,800—7,600 daltons. Finally, 
this factor was shorn not to be insulin, since injection 
of normal mice with insulin does not result in an 
elevation of hepatic citrate levels*
FOREWORD
"Although the path be tortuous and slow,
Although it bristle with a thousand fears,
To hopeful eye of youth it still appears 
A lane by which the rose and hawthorn grow."
from (AT GRADUATION 1905) by T.S. Eliot
I N T . R Q D U C .  T I O N
1. TUMOUR-HOST INTERACTION
(i) Cancer Cachexia
The profound effects of tumour growth on host 
metabolism have been reviewed extensively* Tumour growth 
markedly alters the metabolism of the host, and induces - 
measurable biochemical changes in various tissues and 
organs (Theologides 1972). The resulting syndrome is 
referred to as cachexia, a condition described by Costa 
(1977) as being "characterised primarily by weakness, 
anorexia, and the depletion and redistribution of host 
components". According to Theologides (1972) the 
clinical features of cachexia are the most obvious 
"manifestations" of a profound "systemic derangement" of 
the host metabolism* Shapot (1979) made the observation, 
however, that cachexia should not be recognized as an 
obligatory manifestation of the tumour^s systemic effect 
on the hosto
Various hypotheses have been put forward in an 
attempt to explain the pathogenesis of cancer cachexia, 
and the differences between the metabolism of the tumour- 
bearing host and the non tumour-bearing animal. Although 
the mechanism underlying the capacity of malignant cells 
to grow destructively, infiltrating normal tissues, 
remains obscure, a popular view (Shapot, 1972) relating to 
the problem.was that proteolytic enzymes or toxic 
substances liberated by tumours into their surrounding
environment, would specifically destroy normal cells*
There is a great deal of evidence that tumours 
produce biologically active compounds which affect the 
metabolism of normal cells (Sibley and Lehninger, 1949; 
Suda, Tanaka, Sue, Harano and Morimura, 1962; Begg, 1958; 
Costa and Holland, 1962; Argyris and Argyris, 1962;
Rubin, 1970), Considerable support for this theory was
f
generated by the isolation of "toxohormone" from tumour \ 
cells by Nakahara and Fukuoka (1949). When this 
biologically active compound was injected into normal 
mice, it was shown to stimulate some of the systemic 
effects of tumours in vivo (Kampschmidt, Adams and McCoy, 
1959; Nakahara and Fukuoka, 1958),
Interest in the release of toxic substances by 
tumour cells was revived due to experiments by Holmberg 
(1965, 1968), who isolated a polypeptide that exerted a 
toxic effect on cells in culture. He was able to isolate 
this polypeptide from (a) ascitic fluid of Ehrlich 
carcinoma and landschutz carcinoma: (b) interstitial
fluid of solid transplantable tumours and (c) blood 
plasma of tumour-bearing mice. However, Shapot (1972) 
argues that Holmberg*s data is irrelevant to the problem 
of destructive tumour growth, since he did not test the 
effect of this polypeptide on normal cell lines but on 
tumour cell lines.
On the other hand, Devlin and Costa (I964) considered 
that an alteration in the oxidative and energy conserving 
mechanisms of the host, as a result of tumour growth, may
be related to the cachecticlsyndrome. Devlin and Pruss 
(1958) detected the presence of a substance in the 
25,000 gmax supernatant of a homogenate of the Novikoff 
hepatoma of the rat* This substance was able to un­
couple the oxidative phosphorylation of normal liver 
mitochondria. Nanni and Gasu (1961) were able to 
demonstrate the presence of such substances in the serum 
of sarcoma-bearing rats.
Moreover, Theologides (1972) proposed that 
alterations in the metabolic patterns of the tumour- 
bearing host, and changes in various metabolic equilibria 
and concentrations of metabolites, might be the result of 
allosterio transitions, activations and inactivations of 
various enzymes in the host tissues. Tumour cells, by 
producing low molecular weight molecules, particularly 
polypeptides^would modify the activity of these host 
enzymes, thus throwing host metabolism into a state of 
chaos.
The profound alterations of host organs and functions 
during tumour-growth is considered by Costa (1977) to be 
a result of multiple interactions between destruction, 
attempted repair, homeostasis, and the production of 
biochemical toxins by the tumour. Much attention has 
been focused on distant metabolic effects produced by 
tumours, and since the degree of cachexia bears no simple 
relationship to tumour type or burden, nor can it be 
correlated to the nutritional status of the host, Costa 
(1977) considers the postulation of chemical mediators
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released by the tumour tissue,- inescapable*
Begg (1958) concludes tliat tumours release substances 
into the host circulation, which produce structural and 
functional changes in the tissues of the host, as well 
as facilitating the concentration of metabolites in the 
tumour to the detriment of the host.
Examples of the systemic effects of tumours, which 
are features of the tumour-host relationship (Begg, 1958) 
may be found in alterations of enzyme activity, metabolism, 
nutrition, hormone balance, composition of the blood and 
in the structure of tissues. It becomes clear, 
therefore, that although cancer cachexia is widely 
recognized, the mechanisms involved in producing this 
symptom-complex are still poorly understood.
In a review of tumour and host relationships, Shapot 
(1979) distinguished between two principle and inter­
related groups of manifestations of the systemic effects 
of tumour growth. One of these groups consists of 
changes in the metabolism and hormonal balance of the 
host caused by successful competition of the neoplasm 
with normal tissues for important metabolites and trophic 
factors. The other may be defined as the influence on 
distant tissues manifested by decreasing differentiation, 
changes in enzymic characteristics, diminution of the 
sensitivity of target tissues to the hormones that 
regulate their functions, and disturbances in the negative 
feedback systems which co-ordinate the activities of 
central and peripheral endocrine glands. Some of these
tumour-host relationships will he discussed in later 
sections of this thesis.
Since most studies on tumour-host relationships 
have used animal model systems, the extent to which 
these systems are relevant to that of the cancer patient 
is still obscure* Most animal tumours studied are 
either induced or transplantable, rapidly growing 
malignancies, in contrast to the situation of the cancer 
patient in which the tumour arises spontaneously and may 
be slow-growing.
Nevertheless, a comparative study of the influence 
of tumour growth on host metabolism in mice and man has 
been carried out by Lundholm (1978), He demonstrated 
that a close similarity exists between metabolic 
alterations in skeletal muscle and liver tissue from 
cancer patients and that of mice bearing a transplantable 
methylcholanthrene-induced, non-metastasizing tumour.
These results reinforced the relevance of using 
experimental animal models in the search for the 
mechanisms behind the debilitating effects of tumour 
growth.
A major determinant of cancer cachexia is anorexia. 
Theologides (1972) described the clinical features of 
cachexia, characterized by anorexia, as the most "obvious 
manifestations" of a profound "systemic derangement" of 
host metabolism. He later proposed (1979) that peptides, 
oligonucleotides and other small metabolites produced by 
the tumour cells contributed to the genesis of anorexia
via a peripheral effect- on neuroendocrine cells and 
neuroreceptors, and through a direct effect on the 
central nervous system. Additional factors, including 
emotional and psychological reactions to the disease, 
changes in the senses of taste and smell, would all 
contribute to progressive emaciation of the host. The 
pathophysiology of anorexia in the tumour-bearing animal 
has been difficult to study according to De Wys (1977) 
because of multiple variables that influence the clinical 
picture.
Many metabolic and physiological factors influence 
food intake, and simple starvation results in metabolic 
changes, some of which depress appetite. De Wys (1979) 
is of the opinion that the possible elaboration of 
anorectic peptides by the tumour cells may contribute to 
the anorectic syndrome in cancer patients.
(ii) Metabolic Aspects of Tumour Growth
(a) Carbohydrate Metabolism
According to Holroyde, Gabuzds and Putnam (1975) 
many facets of glucose metabolism in the host may be 
associated with the onset of cancer cachexia, and a study 
of the role of glucose recycling would only add to an 
understanding of this common clinical situation*
Shapot (1972) is in no doubt that the process of tumour 
growth acts as a powerful hypoglycaemic factor in the 
host, and that this tendency to disturb the homeostasis 
of carbohydrate metabolism may result in the derangement
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of host protein and lipid metabolism owing to a forced 
gluconeogenesis. Studies of gluconeogenesis in the 
liver and kidney of tumour and non-tumour bearing animals 
have been carried out. The liver is known to maintain 
normoglycaemia, altering the rate of gluconeogenesis in 
correspondence with fluctuations in the composition of 
the body’s "inner medium" (Exton, 1972; Eisenstein, 1973). 
Cahill (1970) showed that the kidney is also involved in 
this process, since the inhibition of gluconeogenesis in 
both kidneys results in hypoglycaemia in the tumour- 
bearing animal within one hour.
Since gluconeogenesis is under multihormonal control, 
Shapot (1979) discusses several factors which may be 
responsible for the stimulation of gluconeogenesis in 
the host. Insulin would act as an inhibitor, whereas 
glucagon, epinephrine, growth hormone and glucocorticoids 
would accelerate endogenous glucose formation. The 
possibility of the hypersecretion of epinephrine is 
consistent with the phenomenon of a stimulated lipolysis 
in adipose tissues and muscle, described in the tumour- 
bearing host by Shapot (1974, 1979)*
Moreover, there are many observations of the 
elevation of glucocorticoids in cancer patients (Saes, 
1971, 1974) and tumour-bearing animals (Samundjan, 1973). 
According to Herrman and Staib (1969) glucocorticoids 
induce hyperglycaemia in rats, and raise the activity of 
key enzymes of gluconeogenesis. Hyperfunction of the 
adrenal cortex (Weber, 1968; Knox and Sharma, 1968;
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MertvetzoY, 1969) may play;an,-important role in the 
intensification of gluconeogenesis as a response to 
bypoglyoaemio strain of the tumour on the host, and 
that normoglycaemia is ensured by stimulated gluco­
neogenesis from non- carbohydrate sources. The 
impairment of this system would result in hypoglycaemia.
On the other hand, Suda, Tanaka, Sue, Harano and 
Morimura (1966) have reported a predominantly glycolytic 
pathway in the liver of rats hosting a Walker 256 
carc ino sarc oma.
Also, McAllister (1978) has shown thdt the activities 
of phosphofruotokinase and fructose -1,6- diphosphatase 
are not altered in the livers of mice bearing a variety 
of experimental tumours, but there are changes in the 
hepatic content of acetyl-CoA and citrate 
that are opposite to those found in animals under 
gluconeogenic conditions, McAllister concedes however 
that an increased citrate content in liver ^  vivo 
would favour gluconeogenesis by an inhibition of 
phosphofruotokinase. He has shown, by measuring 
NADH/l'JAH ratios, that the cytoplasm of liver cells in 
these animals was in a more reduced state than normal, 
and this would favour gluconeogenesis.
It has also been shown (Engel, 1942; McEadzean 
and Jeung, 1956; Shonfield, Baggot and Gundersen, 1961; 
Landau, Wells, Craig and Leonard, 1962; Grusdeira, 1966; 
Carey, pretlow, Ezdine and Holland, 1966; Tashiro and 
Sakurai, 1970) that the liver of tumour-bearers, both
humans and animals, contains relatively small amounts of 
glycogen. This was thought by Shapot (1972) to be a 
result of an increased need for glucose owing to the 
presence of the tumour. Equally probable is an im­
pairment of the enzyme systems of the liver involved 
either in glycogen synthesis or its mobilisation, as a
result of a toxic action of the tumour.
However, Greenfield (1954) believes it important to 
note that many enzymes in the tissues of the host do not
appear to be affected by the presence of a tumour,
Begg (1958) considers that in some manner the tumour 
produces a selective effect at a distance, with a resultant 
change in the activity of some tissue enzymes, and thus 
in the metabolism of the host, not wholly attributable 
to changes in the hormonal or nutritional status of the 
host, but implicating the secretion of a toxic factor by 
the tumour cells.
(b) Protein Metabolism
Much attention ha.s been centralized on protein 
metabolism in the tumour-bearing host. Mider (1951,
1955) described the tumour as a "nitrogen trap", with 
nitrogen being lost to the host. Mischenko (1940) 
inferred that tumour growth is at the expense of 
assimilation of products of host's muscle protein break­
down. He demonstrated that even during starvation the 
host tissues supply the tumour with amino acids, and that 
cachexia may be caused by an intensified hydrolysis of 
host tissues, Begg (1958) believed that a prominent
15
tumour-host effect is the ability of the tumour to cause 
mobilisation of host protein for the benefit of the 
tumour0
The work of Mischenko and Mider was confirmed by 
Le Page (1952) who demonstrated that after radioactive 
glycine was incorporated into the tissues of tumour- 
bearing rats, subsequent starvation led to a decrease in 
the total activity of the organs of the rats, but to an 
accumulation of the radio-activity in the tumour,
Greenlees and Le Page (1955) extended this study and 
showed that the tumour was indeed a "nitrogen trap" in 
the relative sense only, and does to some degree 
participate in other dynamic exchanges of metabolites 
within the body, whilst still having a tendency to 
accumulate amino acids.
Moreover, data derived by Penninger and Mider (1954) 
from both spontaneous tumours in man and transplanted 
tumours in animals, indicate that nitrogen is stored 
during tumour growth as long as the dietary intake is high 
enough, and the body fat stores great enough to supply the 
demands of the host and the tumour for energy. The 
tumour, however, may continue to grow even in the 
presence of a negative nitrogen balance. The work of 
Lundholm (1975, 1976) supports the view of Shapot (1979) 
that the tumour somehow enhances protein catabolism of 
the host tissues, and may at the same time hinder protein 
synthesis in them. The possibility of the secretion of 
toxic factors by the tumour tissue cannot be excluded
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from an investigation of the mechanisms involved..
However, Mullen, Buzhy, Gertner, Stein, Hargrove, 
Oram^Smith and Rosato (1980) have shown a positive 
correlation between tumour protein synthesis rate and 
protein synthesis rate in adjacent tissue, from the 
organ of tumour origin,which they consider indicates 
that the rates of protein synthesis of tumour cells are 
primarily determined by the inherent nature of the tumour, 
rather than by other environmental or remote factors*
(c) Lipid Metabolism
Haven, Bloor and Randall (1949) showed that in rats 
bearing Walker 256 carcinosarcoma,carcass lipids varied 
inversely with the size of the tumour, and blood lipids 
were increased, in most cases to a very great extent* 
Mider (1948) concluded that the loss of lipid in the 
tumour bearer suggested that the growth of the Walker 
tumour imposes an increased energy reauirement on its
VliOftt ,
Histological techniques employed by Dalton and 
Peters (1944) showed a decrease in stainable lipid in the 
adrenals of tumour-bearing mice, and Aoki (1958) reported 
a decrease in the concentration of adrenal fatty acids, 
cholesterol, cholesterol esters and phospholipids in rats 
bearing a hepatoma* Hyperplasia of the adrenals was
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also characteristic of-rats bearing large tumours in a 
study conducted by Haven (1949) who emphasized that the 
possibility of a hormonal explanation for the lipemia 
observed should be kept in mind*
Shapot (1979) suggested that the mobilized lipids 
are assimilated to a certain extent by the tumour, as 
precursors of its membrane lipids, but mainly by the host 
tissues which "switch over" to the oxidation of fatty 
acids as an energy source, owing to the deficiency of 
glucose intercepted by the tumour. Weber (1966) 
considered hyperlipidemia capable of limiting the 
utilisation of glucose by muscle tissue, whilst at the 
same time inducing the synthesis of enzymes involved in 
gluconeogenesis.
Moreover, Mider (1955) made the observation that 
tumour-bearing rats with lyophilised Walker 256 
carcinosarcoma included in their diet maintained their 
appetite and body weight* Haven and Bloor (1956) 
demonstrated that the active principle involved in this 
phenomenon was in a phospholipid fraction extracted from 
the tumour. The administration of the phospholipid to 
cachectic tumour-bearers led to a gain in body weight and 
activity. Begg (1958) considered this to be the first 
demonstration of a tumour factor that counteracts tumour- 
host effects. He believed it possible that such effects 
are produced both by a "toxohormone" given off from the 
tumour, and by substances such as the phospholipid, 
concentrated in the tumour, and denied to the host.
16
(iii) Effect of Tumour. Growth on the 
Morphology of Host Tissues 
Many striking morphological and biochemical changes 
have been observed in tumour-bearing organisms. Some of 
these morphological changes will now be discussed.
(a) Liver
Ghadially and Parry (1965) undertook a study of the 
morphological changes in the livers of tumour-bearing 
mice in an attempt to establish a morphological basis for 
some of the observed biochemical differences between the 
liver of the normal and the tumour-bearing animal. A 
constant phenomenon associated with tumour growth is an 
increase in liver weight (Annau, Manginelli and Both,
1951; Medigreceanu, 1910). McEwan and Haven (1941 have 
shown that a part of this increase is due to an increase 
in liver water content, and this is borne out by  ^
Ghadially and Parry (1965)o
It is now clear that the increase in liver weight is 
also due to an increase in liver nitrogen content 
(Sherman, Morton and Mider, 1950; Yeakel and Tobias, 
1951*)^ Kay (1961) was of the opinion that protein is 
deviated not only to the growing tumour cells, but also to 
the liver of the cachectic host.
The reasons for these changes is unclear, but 
Harrison (1953) showed that malnutrition was not 
responsible, since in starved animals liver weight de­
creases. Maintenance of food intake did not alter the 
enlargement of liver (and spleen) observed by Stewart and
Begg (1953), that occurs in tumour-hearing rats. Also, 
Toporek (1973) has shown a decrease in the synthesis of 
serum proteins and an increase in the synthesis of liver 
proteins in the livers of tumour-bearing rats. These 
changes according to Toporek (1973) may involve a humoral 
factor secreted by the tumour—cells.
An interesting observation made by Ghadially and 
Parry (1965) was a marked increase in the number of 
lysosomes in the livers of tumour-bearing rats. They 
suggested that an increase in these organelles may be 
involved in the production of cachexia, since the 
lysosomal enzymes may be released and act at sites distant 
from their origin (Be Duve, 1963). The liberated hydro­
lytic enzymes may then be regarded as a mechanism whereby 
normal tissues are broken down and metabolites mobilised 
to meet the metabolic needs of the growing tumour 
(Wiseman and Ghadially, 1958).
Hypertrophy of the spleen of tumour-bearing hosts 
has been frequently observed (Stewart and Begg, 1953;
Konda and Smith, 1973; McAllister, Soukop and Caiman,
1976) and is associated with histological changes.
Rapid enlargement of the spleen has also been 
observed in normal animals following the injection of 
various tumour extracts, in particular "toxohormone" 
(Nakahara and Fukuoka,, 1958; Kampschmidt, Adams and McCoy, 
1959)0 McAllister, Soukop and Caiman (1977) also showed 
that the injection of a cell-free extract of TlX-5
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lymphoma tumour into normal mice induced spleen hyper­
trophy, It was thought that-these-observations 
supported the view of Konda and Smith (1973) that hyper­
trophy of spleen is due to the immune response, and also 
suggest that tumour cell products may be involved in 
producing this effect, a phenomenon investigated in this 
study, which will be discussed later,
(c) Thymus
Atrophy of the thymus is a frequent finding in 
tumour-bearers, Konda and Smith (1973) observed a 
striking decrease in thymus cell numbers over the course 
of tumour growth. Although tempted to conclude that this 
was due to simple thymus involution similar to that 
observed following short-term cortisol treatment, they 
decided that these changes were not identical. They also 
presented indirect evidence that the functional, immuno- 
logically competent cells of the thymus, as in the spleen, 
were increased during tumour-bearing,
Ertl (1973) showed that in rats bearing the Walker 
236 carcinosarcoma, the commencement of thymic atrophy 
could be related to the onset of progressive cachexia.
These observations were confirmed by McAllister, Soukop 
and Caiman (1977),
(d) Adrenals
Shapot (1972) considered that the adrenal cortex 
system of the tumour-bearer would be functioning under 
great strain due to hypersecretion of glucocorticoids 
which may be involved in the enhancement of gluconeogenesis
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in these organisms. ' —
According to several authors (Misukami, Kozako and 
Nishio, 1969; Kawai, Tamura, Tanimoto, Honna and Kuzyya, 
1969; Evgenieva, 1970) there is hypeiplasia of the 
adrenal cortex and hypersecretion of glucocorticoids 
during the early phase of tumour growth. The later 
stages of tumour development are reported to he 
characterized by atrophy of the gland and depletion of the 
glucorticoid reserves. On the other hand, Nakata, 
Suematsa, Nakata, Matsumoto and Sakomoto (1964) have 
described increased hypophyseo-adrenal function and 
increases in plasma corticosterone levels in the advanced 
stages of tumour growth in rats.
Also, Shapot (1972) considers it possible that an 
elevated level of gluconeogenesis in the tumour-bearer is 
caused by the hypersecretion not only of glucocorticoids, 
but of epinephrine (Binard, Kuno and Haynes, 1969) or 
glucagon (Salter, Ezrin, laidlow and Cornell, I960).
(iv) The Effect of Tumour Growth on Biochemical
Characteristics of Host Tissues; with particular 
reference to liver tissue.
The liver plays a fundamental role in the metabolism 
of carbohydrate, fat and amino acids (Newsholme and Start, 
1974) and it is in this tissue the metabolic pathways for 
these metabolites are closely integrated and regulated.
It is for this reason that the following discussion will 
concentrate mainly on the effect of tumour growth on
2C
several of the biochemical characteristics of liver 
tissue.
(a) Liver Oatalase
Studies of liver catalase activity have been important 
in attempts to understand the malignant process 
(Kampschmidt, 1965)o Since the work of Greenstein (1941, 
1942) it has been known that the activity of catalase in 
the host liver is suppressed, and returns to normal after 
surgical removal of the tumour. Greenstein (1941, 1942) 
postulated the secretion of toxic substances by tumour 
cells in an attempt to explain the depression of liver 
oatalase activity in tumour-bearing animals, but was unable 
to demonstrate the presence of these toxins in later 
experiments (1943)»
In a later study, however, Nakahara and Fukuoka 
(1948, 1949, i960, 1958) injected concentrated tumour 
extracts into normal mice and were able to influence liver 
catalase activity in these mice. This material was named 
"toxohormone", and has been the subject of extensive 
reviews (Busch, 1962; Nakagaura, 1952; Nakahara and 
Fukuoka, 1958).
However, Riley (1959) obtained a depression of liver 
catalase activity in mice by injecting homogenates of normal 
liver, kidney and spleen. Lay, Gabrielson and Lipkind 
(1959) also found that spleen homogenates depressed liver 
catalase activity to an extent comparable with tumour 
tissue.
Toxohormone was also found to produce effects other 
than the deoression of liver catalase, Fukuoka and
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Nakahara (1952) observed that injections of toxohormone 
produced thymus involution. Kampschmidt, Adams and McCoy 
(1959) also observed a slight anaemia which develops 24-48 
hours after a single injection of toxohormone, becoming 
more severe after multiple injections* Plasma iron was 
very susceptible to change with small doses of toxohormone 
(Pujii, Kawachi, Okuda, Haga and Yamamura, I960) as were 
increases in the weights of liver, adrenals and spleen 
(Jakubovi^, Keilova and Sorm, 1961; Kampschmidt, Adams 
and McCoy, 1959). Among many other effects, toxohormone 
also decreased liver coenzyme A levels (Kuzin, Sharoukhova 
and Chudinova, 1955). Most of these changes have been 
shown to be similar to those which occur in the tumour- 
bearer. 1
Toxic materials (Kampschmidt, 1965) still seem to 
offer the best explanation for the marked lowering of liver 
catalase activity, and the various effects mentioned above. 
Kampschmidt (1963) considered it unlikely, however, that 
the tumour tissue itself is the source of the toxin, and 
other possible sources could be bacterial or viral 
contaminants or reactions of the host animal to the 
presence of the tumour. The possibility that viral con­
tamination of the tumour may be responsible for or involved 
in producing some of the observed effects of tumour growth, 
will be discussed in more detail in a later section of this 
thesis.
(b) LI^/BP COENZYME A
Various workers have investigated the levels of 
coenzyme A in animal tissue, particularly rat tissue,
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following gluconeogenic stimuli such as starvation and the 
induction of diabetes (Start and Newsholme, 1968; Herrera 
and Frienkel, 1968) and following treatment with various 
hormones (Greenbaum Gumaa and McLean, 1972; Exton and 
Harper, 1972). Hombrook, Buch and Lowry (1965) 
demonstrated changes in the levels of liver coenzyme A 
during glycogen synthesis induced by lactate and 
hydrocortisone.
However, there is little reference in the literature 
to the content of this regulatory intermediate in the 
livers of tumour-bearing animals. Shils, Friedland and 
Shapiro (1956) did measure the amount of coenzyme A and 
various vitamins in the liver and other organs of tumour- 
bearing mice, but did not investigate in non tumour-bearers, 
Earlier work by Higgins, Miller, Price and Strong (1951) 
measured the levels of coenzyme A in rat livers and 
tumours, and found that coenzyme A is present in 
appreciably lower amounts in rat liver tumours than in 
normal liver, but no detailed analysis of the levels of 
this metabolite in tumour and various other tissues had 
appeared before this work.
Since Rapp used a non-specific assay method for 
determining coenzyme A (Handschumacher, Muller and Strong, 
1951) it is not possible to interpret his data in terms of 
the actual form of the coenzyme present, since this method 
also measures acetyl-coenzyrae A, acyl thiol esters of 
COenzyme A and various precursors in the biosynthesis of 
the coenzyme (Oavallini, Mondovi, De Marco and Perro-Luzzi, 
1959) . Rapp (1975) did suggest that the phenomenon he
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observed, however, might be reponsible for some of the 
debilitating systemic effects observed during tumour 
growth*
Studies carried out by Caiman and McAllister (1975a, 
1975b) and McAllister, Soukop and Caiman (1976) investigated 
in great detail the acetyl-coenzyme A and free coenzyme A 
content of liver in tumour and non tumour-bearing mice.
These studies showed that in mice bearing the TLX-5 
lymphoma, there were significant reductions in the hepatic 
contents of acetyl-coenzyme A, and free coenzyme A which 
could be detected as early as 24 hours after tumour implant. 
Total coenzyme A, which is the sum of acetyl-coenzyme A, 
oxidised coenzyme A and reduced coenzyme A, remained at 
significantly low levels throughout the period of the tumour 
growth. Two days after tumour implant acetyl-coenzyme A 
levels returned to normal* These early changes in
y
coenzyme A levels occug^d before visible signs of cachexia 
became evident, suggesting that cachexia was not a 
prerequisite for these metabolic abnormalities.
McAllister, Soukop and Caiman (1976) also studied the 
levels of these metabolites in the livers of mice bearing 
Sarcoma-180 and C5H-mammary tumours, and found a similar 
pattern of changes occulting. The food and water intake 
of these animals was monitored and the overall situation 
found to be one of anorexia. Mice injected with a cell- 
free preparation of the TLX-5 lymphoma also showed 
decreases in hepatic coenzyme A levels, and in mice bearing 
the C5H-mammary tumour, these changes reverted to normal
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after curative resection of. the tumour.
(c) Liver Citrate
Dickens (1941) showed that a high concentration of 
citric acid was characteristic of rapidly growing tissue, 
including a variety of animal and human tumours, A study 
by Haven, Randall and Bloor (1949) showed that in rats 
bearing Walker-256 carcinosarcoma, the citrate content of 
liver, kidney and spleen was higher than that found in 
corresponding organs of control animals. It was suggested 
that the presence of neoplasm in tne animal may have caused 
the various organs to assume "chemically neoplastic 
qualities" resulting in an increased formation or decreased 
utilisation of citrate.
The hepatic citrate content of tumour bearing mice ha,s 
also been studied extensively by Caiman and McAllister 
(1974a, 1975b) and McAllister, Soukop and Caiman (1976), 
who observed significant increases in the hepatic citrate 
content of mice bearing the TLX-5 lymphoma, Sarcoma-180 
and C5H-mammary tumours. In the case of the TLX-5 
lymphoma-bearing mice, this change could be detected 24 
hours after tumour implant. A similar pattern of changes 
was observed in mice bearing the other experimental tumours, 
and these changes were shown to return to normal after 
curative resection of the tumours of mice bearing 
C5H-mammary tumours.
The direction of changes in both citrate and coenzyme 
A levels described by these workers is opposite to that 
found in normal animals under conditions of forced
gluconeogenesis (Wieland, 1966; - Start and Newsholme,
1968)0 McAllister, Soukop and Caiman (1976) are of the 
opinion that a factor or factors released from the tumour 
cells cannot he excluded from the aetiology of these 
changes. The evidence they present for this is, as 
previously mentioned, the ability of a cell-free preparation 
of TLX-5 lymphoma cells to bring about these liver 
metabolite changes, and the reversion of these changes to 
normal after the curative resection of tumour in mice 
bearing the C5H-maramary tumour.
It is of interest that McAllister, Soukop and Caiman 
(1976,1977) also examined the influence of TLX-5 lymphoma 
on mouse spleen, thymus and epididymal fat pad weight.
Their results show that thymus weight decreases significantly 
24 hours after tumour implant and continues to do so over 
the period of tumour growth. Spleen weights were shown to 
increase at about two days of tumour growth, with a 
concomittant increase in epididymal fat pad weight*
(V) Tumour-Derived Metabolic Modulators
In previous sections of this Introduction, a great 
deal of reference has been made to the concept of tumour- 
derived toxins or chemical mediators (Kampschmidt, Adams 
and McCoy, 1959; Okudu, Ikagami and Fujii, 1972;
Olivares, 1970; Ohashi and Ono, 1959; Nakahara and 
Fukuoka, 1958, 1949; Greenstein, Lenrette and Waite^ 1941; 
Shapot, 1972, 1979; Costa, 1979). Costa (1977) believed 
that the unambiguous demonstration of the existence of the 
tumour toxins, and the definition of their role might be a
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significant breakthrough in oncology. In consequence, a 
great deal of work has been carried out in attempts to 
elucidate and characterize substances of tumour origin 
which are responsible for modifying the tumour environment 
in order to facilitate its growth. Some authorities 
consider that the presence of a circulating toxin may still 
offer the best explanation for some of the systemic effects 
of a growing tumour (Kampschmidt, 1977). Perhaps the 
most well documented tumour toxin or metabolic modulator 
is "toxohormone", which has been discussed, previously.
Recently another phenomenon has been elucidated, that 
of tumour angiogenesis. Experiments by Greenblatt and 
Shubik, (1978) suggest that tumours stimulate 
neovascularization by releasing a "diffusible" material. 
This material can be isolated from both the solid and 
ascites forms of tumours (Folkmann, Merler, Abernathy and 
Williams, 1971) and is known as tumour angiogenesis 
factor (TAP), The presence of TAP in tumour cell 
cytoplasm and nucleus, and in tumour cell cultures has 
been demonstrated (Tuan, Smith, Pollanann and Merler, 1975; 
Polkmann, 1974). TAP has been purified from tumour cell 
nuclei (Polkmann, Merler, Abernathy and Williams, 1971) 
and found to be a non-histone protein, Tuan, Smith, 
Polkmann and Merler, (1975) then showed this protein to be 
capable of producing neovascularization in vivo, and in 
later work, Weiss, Bro’wn, Kuman and Phillips (1979) 
isolated a low molecular weight, non-protein component from 
rat Walker-256 tumours, which v/as highly active in inducing
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angiogenesis in vitro, and capable of stimulating the 
growth of endothelial cells in culture. It is thought 
that once the chemical nature of this angiogenic factor is 
established, it may have both prophylactic and diagnostic 
implications in human malignant disease (Weiss, Brown, 
Kumar and Phillips, 1979).
There are many other reports in the literature 
concerning the elucidation of tumour-derived toxins.
Ting, Tsai and Rogers, (1977) reported the presence of a 
humoral factor in the ascitic fluid of mice bearing an 
intraperitoneal tumour, and in the pleural effusions of 
cancer patients. This factor was found to promote the 
growth of a murine tumour and to suppress cell-mediated 
immunity. It was also shown that host animals who recov­
ered from the immunosuppressive state produced a serum 
factor that could neutralize the immunosuppressive effect 
of the humoral factor, and this counter-factor may play 
an important role in the control of tumour growth.
Moreover, Henriksen and Law, (1977) presented data 
suggesting that mKSA and L1210 cell-free ascitic fluids 
contain a. component which is able to prolong the 
"immunologically paralysed state" of tumour-bearing 
animals, and involves a continuous interaction between 
tumour cells and host. This component has been partially 
purified, and is described as a low molecular weight, 
neutral compound. The authors suggest that if all 
oncogenic tumours secrete, or induce the host to 
manufacture tumour growth-promoting substances, then the
isolation and chemical- characterisation of these substances 
could be of great diagnostic and therapeutic importance.
More recent work carried out by Cheung, Oantarrow 
and Sundharadas, (1979) described another low molecular 
weight factor produced by various mouse tumours and by 
mKSA and LLC cells in tissue culture. This is a 
macrophage modulating factor which affects closely related 
macrophage properties such as spreading and migration.
It also inhibits lipopolysaccharide-induced tumoricidal 
activity of macrophages, and is thought to be of tumour 
origin. The point is made, though, that tumour tissue is 
known to contain host cells, bacteria and in some cases, 
viral contamination. Degradative events may be occurring 
in the vicinity of the tumour cells, hence it may be, argued 
that.this factor may not be a product of tumour cells*
Some mouse tumours are known to contain lactate 
dehydrogenase virus, (Riley, I960) and the appearance of 
this macrophage modulating factor may possibly be related 
to the presence of this virus. This possibility was 
ruled out by the observation that LLG and mKSA cells 
cultured in vitro for five passages did not contain the 
virus, but contained macrophage-modulating factor (Cheung, 
Oantarrow and Sandharadas, 1979).
Other examples of tumour-derived chemical mediators 
include the isolation by Nair and De Omo (1975) of a 
soluble fraction from solid, spontaneous, primary mouse 
mammary tumours which stimulated the growth of density- 
inhibited mouse embryo cells in monolayer culture. The
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possibility of this stimulatory .effect being due to the 
presence of a virus was excluded. Nepom, Hellstrom and 
Hellstrom, (1979) were able to purify and characterise a 
tumour specific blocking factor from the sera of mice with 
growing, chemically-induced sarcomas, and Hellstrom, and 
Hellstrom (1979) demonstrated the enhancement of tumour 
growth by tumour-associated blocking factors. Elleman and 
Eldinger, (1977) found suppressive factors in the ascitic 
fluid and sera of mice bearing several types of ascites 
tumour. Their results suggest the existence of a wide- 
ranging series of tumour and host factors that influence 
both tumour growth, and immunological responses in vitro*
Most of the recent work studying tumour-derived 
chemical mediators has concentrated on the isolation of 
substances which affect measurable immunological 
parameters. On the other hand, Vaage and Agarwall (1977) 
used the production of ornithine decarboxylase as an 
indicator of mitotic activity in neoplastic cells. Their 
results show that the level of production of ornithine 
decarboxylase in these cells can be used to detect, in 
serum and malignant effusion fluid, factors which are 
associated with progressive neoplastic growth, and v/hich 
may influence the replication of neoplastic cells.
Moreover, McAllister, Soukop and Caiman (1976,1977) 
were able to demonstrate the existence of factor(s) in the 
cell-free ascitic fluid from TLX-5 lymphoma-bearing mice 
which was able to influence liver metabolism in normal 
mice, as measured by increases in hepatic citrate content
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and decreases in hepatic coenzyme A levels. An attempt 
was therefore made in this study to isolate and 
characterise the factor or factors present in this cell- 
free tumour preparation responsible for increasing hepatic 
citrate levels in normal mice, to determine whether it was 
a host or a tumour product, and whether or not the 
observed effects were caused by viral contamination of the 
tumour cells. Experimental procedures and results will 
be discussed in later chapters of this thesis.
The TLX-5 Lymphoma tumour model was chosen for this 
study since ascitic fluid from mice bearing this tumour 
contains a multiplicity of host and tumour factors which 
may be involved in producing the observed metabolic 
abnormalities. Large volumes of ascitic fluid can be 
readily obtained from relatively few tumour-bearing mice* 
The tumour is also fast-growing since it will kill mice 
injected intraperitoneally with 2x10^ viable cells within 
7-8 days.
2. VIRAL CONTAMINATION OE EXPERIMENTAL TUMOURS
In search of a simple diagnostic test for the early 
detection of malignant disease, many investigators have 
looked for differences in the activity of various serum or 
plasma enzymes in the tumour and non tumour-bearing host. 
Hill and Levi (1954) found that the enzyme lactate 
dehydrogenase (LEE) was elevated in the serum of a number 
of patients with malignant disease, Hsieh, Suntzeff and 
Gowdry (1955) reported similar findings in tumour-bearing 
mice.
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Alii le studying the relationship between enzyme 
elevation and tumour growth/ Riley (i960) found that when 
plasma or cell-free extracts from the tissues of the
tumour-bearing mice were injected into normal mice, the 
recipients developed a significant increase in serum LDH 
activity within 48 hours. Subsequent studies showed 
that the IDE agent was a virus (Bladen, 1969; Notkins, 
1965). This lactate dehydrogenase virus (LDV) has been 
shown to be carried as a contaminant by a number of 
serially transplanted mouse tumours (Notkins, 1965).
In addition to increasing serum LDÏÏ levels, a number 
of other enzymes were shown to be elevated in the serum of 
mice infected with LDV, in particular isocitrate dehydro­
genase (Notkins, 1965). Because of the increase in 
glycolytic enzyme activity in the serum of infected mice, 
Riley (1963) studied the glycolysis of infected and non­
infected tumours. He found that the anaerobic glycolysis 
of a methylcholanthrene-induced tumour which had been 
infected with LDV was higher than its non-infected 
counterpart, but the reasons behind this are unknown.
There are several ways in which tumours can be freed 
from LDV contamination. One example is by passaging the 
tumour through rats (Notkins, Berry» Moloney and 
Greenfield, 1962), Another method is by passaging the 
tumour through cell lines which do not support LDV 
replication, or by several passages through tissue culture 
(Plagemann, Watanabe and Swim, 1962).
Later work by Mergenhagen, Notkins and Dougnerty
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(1967) has shovai that the infection of adult mice with 
LDV erQiances the antibody response of the mice to 
intraperitoneal injections of human gamma-globulin, showing 
that the virus is acting as an immunological adjuvant.
On the other hand, a report by Riley and Speckman (1976) 
found the LDV to function as an immunosupressant and 
tumour-enhancing agent, through its adverse effects on 
T and B lymphocytes. The destruction of T lymphocytes 
and host tissue by the virus is apparently caused 
indirectly through a typical stress response that includes 
an elevation in plasma corticosterone, which is known to 
"attack" lymphoid cells and tissues (Santisteban and Riley, 
1973; Spackman and Riley, 1976)*
All of these findings emphasize the need to screen 
for the presence of this ubiquitous virus, especially in 
experimental systems in which tumour lines are maintained 
by passage in mice, and where there is a high risk of cross­
infection, as after surgical manipulation.
However, this LDV agent has not been identified in 
species other than mice (Notkins, 1963), and it is 
interesting to note that Hill and Levi (1934) found 
elevated serum LDH levels in patients with malignancies.
Bodansky and Scholler (1956) confirmed the increase in 
serum LDH activity in rats, and Begg (1958) considered 
that these observed increases in serum LDH were a result 
of the release of enzyme from the tumour, but this has not 
been confirmed.
Since this study involved working with a murine tumour, 
the TLX-5 lymphoma, and various cell-free preparations of 
this tumour, it was thought necessary to screen for the 
presence of the LDV in the tumour cells. The first 
method of detection involved electron microscope 
examination of the tumour cells. The second method 
involved measuring LDH activity in the serum of mice 
injected with tumour cells or tumour cell-free 
preparations, and comparing these levels with those of 
normal mice.
In order to eliminate the presence of this agent 
from the tumour cells, the cells were passaged through 
tissue culture for at least five passages to ensure they 
were free from contamination. Cell-free tumour preparations 
were ultracentrifuged at 240.OOOgmax. for 24 hours to 
eliminate any viral particles present. Results of this 
work will he discussed in later chapters.
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OUTLINE OP PRESENT STUDY
This present study looked at the factor or factors 
present in the ascitic fluid of mice bearing the TLX-5 
lymphoma, responsible for increasing hepatic citrate 
levels, as described by Caiman and McAllister (1975a, 
1975b), and McAllister, Soukop and Caiman (1976, 1977)*
It was not known whether this biologically active factor(s) 
was of host or tumour origin, and the possibility of viral 
contamination of the tumour being involved in producing 
the observed metabolic effects (Notkins, 1965) could not 
be discounted. Tumour cells grown both in vivo and in 
vitro were examined using electron microscopy to determine 
whether or not a virus was present. Ultracentrifugation 
of a tumour cell-free preparation was carried out to 
remove any viral particles present, without removing 
or in any way affecting the biological activity of the 
preparation. The biological activity was determined by 
measuring hepatic citrate levels in mice injected with the 
preparation and comparing these levels with those of mice 
given a placebo injection.
Biological activity was also detected in the 
"conditioned" cell-free growth medium from in vitro grown 
tumour cells, indicating tha.t the factor or factors 
involved is primarily of tumour cell origin.
Characterisation of the active factor(s) present in 
the cell-free ascitic fluid from tumour bearing animals 
involved heat-treatment, dialysis, trypsin treatment and 
ammonium sulphate fractionation of the preparation* This 
Was to determine if the factor(s) was orotein in nature.
Ammonium sulphate precipitation of the cell-free 
preparation resulted in a considerable purification in 
terms of protein content, as did ultracentrifugation*
It was then necessary to obtain a relatively 
€■
homogenous sample of this biologically active factor(s) 
in order to determine molecular weight. Gel filtration 
is a valuable technique for the isolation and purification 
of substances of biological origin, particularly proteins 
(Andrews, 1970), and can also be applied to the 
determination of molecular weights of unknown compounds, 
Sephadex is particularly useful for the chromotography of 
biological substances, as there is no irreversible retention 
of small amounts of substances on the column. It is 
therefore useful for analytical purposes* This method 
was used to fractionate virus-free ascitic fluid, to 
attempt to isolate the biologically active component(s)*
Another method which can be used to determine the 
molecular weights of unknown compounds, particularly 
proteins, is gel electrophoresis in polyacrylamide gels.
The homogeneity of samples during purification procedures 
can also be determined using this technique. The method 
has the advantage of rapidly separating complex mixtures 
of proteins with high resolution (Brewer, Pesce and 
Ashworth, 1974; Zahler, 1974) and requires only small 
amounts of protein, Por these reasons this method 
was employed to determine the homogeneity of fractions 
obtained from gel filtration experiments, which had 
demonstrable biological activity. The molecular weight
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of proteins present in these biologically active fractions 
WAS also estimated.
There were therefore 3 main areas of study involved 
in this work, and these are summarized below;-
(1) The effects of TLX-5 lymphoma cells and cell-free 
extracts on mouse hepatic citrate levels, and 
characterization of the factor (s), present in ascitic 
fluid from mice bearing TLX-5 lymphoma, responsible 
for increasing hepatic citrate levels.
(2) The fractionation and isolation of this factor (s) from 
ascitic fluid and the determination of its molecular 
weight,
(3) An investigation of the possibility that this metabolic 
effect of cell-free extracts of TLX-5 lymphoma was due 
to contamination of the tumour by viruses.
:) /
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MATERIALS Aim METHODS
1. TUMOUR AM) ANIMALS USED
(i) Animals
In all studies reported, 3-4 month old, male CBA mice 
were used. These mice were from an inbred strain obtained 
from the Animal House of the University Department of 
Surgery, and maintained in the Animal House of the 
University Department of Clinical Oncology by conventional 
inbred mating systems^ ov\ a  C R . M  d\eV;, ( .
All mice were kept on a 12 hour light-dark cycle, and 
given water and food ad libitum. Prior to the beginning 
of each experiment mice weighing 25-35 grammes were selected 
and allowed to adapt to their new environment for at least 2 
days, to prevent undue stress securing which might adversely 
affect experimental results.
(ii) Tumour
The tumour used was the TLX-5 lymphoma. This tumour 
Was first induced by Dr. D.I. Connell at the Institute of 
Cancer Research, London, by whole body X-irradiation of 
CBA mice. The enlarged thymuses were subsequently 
transplanted into CBA mice (McAllister, 1978), Male CBA 
mice bearing an ascitic form of this tumour were obtained 
from the Animal House of the University Department of 
Surgery, and the tumour was routinely passaged every 7 days 
thereafter,
Histological examination of the tumour cells revealed
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that the tumour is extremely invasive, poorly differentiated
c^t'oV: ^
and uncapsulated (Willmott1980), Histological examination
etaL
of the livers of mice bearing this tumour (Y/illmott1980) 
revealed liver metastasiso
(iii) Routine Tumour Passage
The tumour was passaged routinely every 7 days. Mice 
bearing the ascitic form of the tumour were sacrificed and 
the carcasses swabbed with absolute alcohol. Ascitic 
fluid was removed from the peritoneal cavity using a 
sterile needle and syringe, and the number of tumour cells 
counted using an Improved Nebauer Counting Chamber. The 
number of viable cells were determined using Trypan-blue 
(Paul, 1970), and the cells diluted to a concentration of 
2x10*^  viable cells per ml, with sterile phosphate-buffered 
saline (PBS; 8.0g NaCl, 1.21g KgHPO^, 0,348' KH^PO^ per 
litre distilled HpO). Normal mice were then injected 
with 0,1ml of this oell suspension, intraperitoneally 
(i.p.). These animals were sacrificed 7 days later and
I
the procedure repeated,
(iv) Control Animals
All animals used in control experiments were injected 
i.po with 0,1ml of sterile PBS, unless otherwise stated.
(v) Preparation of Tumour Extracts
(a) Cell-free ascitic fluid (Supernatant-1, SNl)
Tumour cells were harvested as previously described. 
Ascitic fluid from several mice was mixed and the number of 
viable tumour cells counted. The ascitic fluid v/as then 
diluted with sterile PBS to give a viable cell 
concentration of 2]clO^  cells per ml, unless otherwise 
indicated.
^ Visking dialysis tubing was used (Macfarlane Robson Ltd.). 
The tubing was rehumidified before use by placing it in 
boiling water for 5 minutes.
The ascitic fluid was then subjected to high speed 
centrifugation at 4^0 in a Beckman 15-50 Ultracentrifuge, 
This was carried out for 4 hours at 100,000gmax. and 
produced a supernatant from which all the sub-cellular 
organelles, as well as the tumour cells, had been removed 
(Bigure 1, SNl), The supernatant was then carefully 
removed and stored at -70°0, if not immediately required.
To ensure that SNl was completely free of tumour cells, at 
least 2 mice were inoculated with the preparation and 
observed for 21 days to find out if tumour growth occurredo
(b) Virus-free ascitic fluid (Supernatant-2, SN2)
SNl was prepared and subjected to high speed 
centrifugation at 4^U in a Beckman 15-50 Ultracentrifuge, 
for 24 hours at 240,000gmax, This produced a supernatant 
from which all viruses had been removed (Notkins, 1965)o 
The supernatant was then removed and stored as for SNl*
(c) Heat-treated SNl and SN2
10ml aliquots of SNl and SN2 were heated to 100^0, 
with stirring, for 5 minutes, then cooled rapidly on icoo 
Precipitates were then removed by filtration.
(d) Dialysis of SNl and SN2
5ml aliquots of SNl snd SN2 were dialysed for 24 hours
at 4^0, with gentle stirring, against 1 litre of sterile 
*
PBS.
(e) Ammonium sulphate precipitation of SNl and SN2 
0-35 per cent saturation
4,85g (NB^^gSOq was added, slowly, with stirring, to 
25 ml of S2T1 and 25ml of SN2, at 4^0. The samples were
then centrifuged at 4°C for 15 minutes at 20,OOOr.p,m., in
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figure 1—  k "" ■! I ■! I" «Ml I I
PREPARATION OF C ELL-FREE ASCITIC FLUID  
AND "VIRUS-FREE" ASCITIC FLUID
T L X -5  Lymphoma-Bearing Mouse
Mouse killed. Ascitic fluid 
containing tumour cells removed 
from peritoneal cavity.
Ascitic fluid spun at 100, OOOgmax 
for 4 hours (to remove tumour 
cells) at 4OC.
I
C ell-free ascitic fluid spun at 
240,000gmax lor 24 hours (to 
remove virus particles) at 4°C - 
Supernatant-1,
1
"V irus-Free" ascitic fluid - 
Supernatant-2.
Injected into CBA Mouse i.p , 
at concentration of 2 x 10® 
cells (or cell equivalent 
concentrations)
Increase in mouse liver 
citrate levels detected 24 
hours after injection
4-1
a Sorvall RG-5 centrifuge. The.supernatants were removed 
and retained for further precipitation with (NHq)280q.
The pellets were redissolved in 25ml of sterile PBS, and 
represented the 0-35*|o (NH^) pSO4. fraction.
35-65 Yo (NH/| ) 98O4 precipitation
4.6g (NHqïgSO^ was added to SNl supernatant retained 
from the previous precipitation step. This was added 
slowly, with stirring, at 4^0, The sample was centrifuged, 
as described in the previous step, and the pellet re­
dissolved in 25ml of sterile PBS.
Traces of (NH4.)2S04 were removed from the redissolved 
precipitates by dialysis at 4°G for 24 hours against 2 
litres sterile PBS.
(f) Treatment of SN2 with Trypsin
25mg of trypsin (Sigma) was added to 1ml of SN2 and 
to 1ml of sterile PBS, samples were vortexed and incubated 
at 25°G for 30 minutes. 31.25mg of trypsin inhibitor 
(Sigma) was then added to each sample, vortexed and 
incubated at 25^0 for a further 30 minutes. Control 
samples of SN2 and sterile PBS were incubated at 25^G for 
60 minutes. Biological activity was determined for each 
sampleo
(g) Resusponsion of SN2 pellet (obtained from (b) )
The pellet obtained during the preparation of SN2 
was resuspended in an equivalent volume of sterile PBS 
by extensive homogenisation. In order to keep the sample 
cool, this process was carried out at 4^0. A control 
sample of SN2 was treated in the same way.
4o
(vi) Treatment of Animals ;;
Tumour cell suspension and cell-free preparations 
described in (v (a) - v (g) ) were injected ivp. into 
experimental mice at a cell or cell-equivalent concentration 
of 2x10^ per 0.1ml, where mice were given 0.1ml, Mice 
were routinely killed 24 hours after injection, unless 
otherwise indicated, and their livers rapidly removed and 
hepatic citrate content determined, as a measure of the 
biological activity of the various preparations,
(vii) Sacrifice of Animals
All animals were killed rapidly by cervical dis­
location. This was to prevent any undue stress to the 
animal which might adversely affect experimental results,
2- PEBPAHATIOM OF TISSUES AtTD EHZYMATIC 
DETSailMATION OF CITRATE
(i) Preparation of Tissue 
Breeze-clamp ing 
The clamp used was constructed from an ordinary set 
of pliers 26cm in length, to which had been welded 2 
stainless steel plates whose dimensions were 6cmx5cmxl.5mm* 
These plates were of such a size that a mouse liver, when 
freeze-clamped, did not extrude beyond their edges.
Before freezing the liver, the tongs were pre-cooled 
in an aluminium tray containing liquid Np* 1 stoneware 
mortar and pestle were also pre-cooled in this way. 
Preweighed homogenising vessels (Uniform) with a capacitj-^  
of 15ml were precooled in Dry-Kold for at least 1 hour 
before use.
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The mouse was killed and .the liver rapidly exposed 
by a transverse upper abdominal incision, the liver 
removed, placed onto the precooled plate of the clamp, 
immediately clamped and the whole immersed into liquid Ng 
(Caiman and McAllister, 1975a, 1975b). The frozen liver 
was kept immersed in liquid Kp at least 3 minutes, 
then was reduced to a fine powder using the precooled 
mortar and pestle. To prevent the tissue thawing out 
during this procedure a small volume of liquid was 
added to the mortar. The powdered liver was then 
transferred to a preweighed, precooled homogenising vessel* 
After a rapid reweigh, the samples were stored in Dry-Kold 
or at -7000.
(ii) Extraction and Assay of Liver Pitrate
The reactions involved in the enzymatic determination 
of citrate are;
(1)
Pyruvate •+ NADH — — > Lactate + NAD
(2)
Citrate - ,■> Oxaloaoetate + Acetate
^ (3)
Oxaloaoetate 4 NADH + H  Malate *4* NAD
The enzymes catalysing the above reactions are;-
(1) Lactate dehydrogenase (E.G. 1.1.1.27), (LDH),
(2) Citrate Lyase (E.G. 4ol.3o6), (GL).
(3) Malate dehydrogenase (E.G. 1*1.1*37), (MDH).
Changes in the absorbance of NADH at 366nm, were measured 
The extinction coefficient of NADH being 3*30 at this wave­
length, The procedure for determining citrate is that' 
described by Bergmeyer (1965).
4-
Reagents '
(1) 0,6 M perchloric acid.
(2) 0.2 nM citrate standard.
(3) 0.03 M zinc chloride.
(4) 0*1 M triethanol amine buffer,
(5) 0.12 M sodium hydrogen carbonate,
(6) 10 mg ^ NADH (reduced form) dissolved in 1,28ml of 
solution (5).
(7) 598U/ml LDH suspension.
(8) 1495U/ml MDH suspension,
(9) lOOU/ml GL suspension.
All solutions and suspensions were kept under 
refrigeration. Enzymes and NADH were supplied by 
Boehringer, London. Solution (6) was used within a few 
hours' of preparation. Solutions (l)-(4) could be kept up 
to 12 months if refrigerated, and according to the 
manufacturers, (Boehringer Mannheim) LDH and MDH suspensions 
were stable for several months if stored dessicated, under 
refrigeration. The CL suspension lost about 10^,activity 
within 1 month of preparation.
Methods
4.0ml ice-cold perchloric acid was added to frozen, 
powdered liver in the homogenising vessel (the weight of 
liver present being first determined). This was mixed 
rapidly, then immediately homogenised using a precooled 
teflon pestle, with two series of passes at full speed. 
Samples were kept on ice for 30 seconds between each 
series of passes* A Potter Elvehjen (1936) type 
homogeniser was used, driven by a motor (Gitenco) which
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gave a maximum speed of'approximately 7,200r.p*m..
The homogenate was centrifuged at 3>000gmax. for 10 
minutes at 4^0, and the pellet discarded. Perchloric 
acid was removed from the tissue extract (supernatant) by 
precipitation with potassium carbonate. The pH of the 
supernatant was adjusted to 7.5 using 211 potassium 
carbonate, the final adjustment being made with 0*01M 
potassium carbonate. The sample was cooled on ice for 10 
minutes and the precipitate removed by centrifugation at 
5,000gmax. for 15 minutes at 4°0. The volume of the 
supernatant was then adjusted to 10ml with triethanolamine 
buffer. The citrate content of this tissue extract was 
then determined spectrophotometrically. A Gilford-250 
Spectrophotometer was used, and measurements made at a 
wavelength of 566nm., pathlength 1cm and temperature of 
25^0, in glass cuvettes, *
The following were pipetted into the cuvettes:- 
triethanolamine buffer 2,0ml
2-HADH 0.06ml
zinc chloride 0,01ml
sample 0.09ml
LDH 0,01ml
MDH 0.01ml
After mixing, the absorbance was allowed to stabilise, and 
the final absorbance, (Al), noted. Then 0,01ml GL was 
added to cuvette, mixed, and the absorbance noted at 
1-minute intervals until the reaction stopped (about 10 
minutes). The final absorbance, (A2), was noted. A
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^  A recovery of between 90-95.5% was always obtained using the 
citrate standard solution.
standard citrate solution was included with each set of 
samples to he assayed. 0,09 ml of the standard solution 
diluted to a concentration of 0.18 \M was used.
Citrate levels were calculated from;- 
A A » (Al - A2)
A A X 1.01 X supernatant volume (ml) - umol, citrate per 
weight of liver used (g)
gram liver wet weight ( Me Allister, 1978)
3. STABILITY OP BIOLOGICAL MATERIALS AT -70°0.
(i) Stability of Citrate in Erozen, Powdered Liver
The livers of 10 untreated mice were freeze-clamped 
and powdered, as previously described. The powdered 
liver samples were ’’pooled", samples of approximately 700mg 
removed and their citrate content assayed. The remainder 
of the powdered livers was stored at -70^C, and samples 
removed at intervals up to 14 days and the analyses 
repeated.
(ii) Stability of SNl and SN2
Sî^ l and SDT2 were prepared as previously described. 
Aliquots were immediately injected i.p. into 2 separate 
groups of 6 mice. The remainder of SÎT1 and SN2 was stored 
at -70^0, The treated mice were killed 24 hours after 
injection and their liver citrate content measured. This 
procedure was repeated at various time intervals up to 
60 days, to determine the effect of storage at -70^0 on the 
biological activity of SNl and SN2.
4. DETERMINATION OB PROTEIN CONCENTRATIONS
(i) The Bradford Method
This method described by Bradford (1976) is a rapid
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and sensitive method which can be. used for the quantitation 
of microgram quantities of protein.
Reagents
(1) 1“|ô(y//v) Coomassie Brilliant Blue G-250; 4o7^l(w/v) 
ethanol and 8.5 % ( w/v) phosphoric acid,
(2) Standard Bovine serum albumin (BSA) solutions 
consisting of 5, 10, 15 and 20 ug BSA per 0.1ml PBS, 
respectively.
Method
0.1ml of standard protein solutions and samples were 
pipetted into separate 12 x 100mm test tubes. A blank 
consisting of 0.1ml PBS was also included. A volume of 
2ml of the protein reagent (solution 1) was added to each 
tube, and the contents mixed by vortexing. The absorbance 
at 595nm, was measured after 2 minutes and before 60 
minutes, in 321I volume glass cuvettes against the reagent 
blank. The concentration of protein in the standard 
solutions was plotted against their corresponding 
absorbance, and linear regression used to find the line of 
"best fit" for the data points. This standard line was 
then used to determine the protein of the unknown samples. 
This method was sensitive when- measuring protein 
concentrations in the range lO-lOOug per ml. Samples with 
a protein concentration above this range were diluted with 
a knov-m volume of PBS until the concentration fell within 
the measurable range,
(ii) Absorption of Protein at 230nm.
This method of measuring protein was also used, in 
most cases to supplement the data obtained using the 
Bradford method.
Reagents
Standard BSA solutions'consisting of 5, 10, 15 and 
20 ug per 2ml PBS respectively.
Method
The absorbance of samples and standards were measured 
at 250nm in 1ml volume quartz cuvettes against a PBS blank. 
The concentration of protein in the standard solutions was 
plotted against their corresponding absorbance, and linear 
regression used to find the line of "best fit" for the data 
points. The resultant standard graph was used to determine 
the concentration of protein in the unloaovms.
5. ESTIMATION OP MOLECULAR \YEIGHT BY GEL PILTRATION
Gel filtration is a valuable technique for the 
estimation of the molecular weights of unknown compounds, 
particularly proteins (Andrews, 1970). Por the purpose of
these studies Sephadex G-lOO was used. This Sephadex-type
has a molecular weight fractionation range between 
4,000-150,000 daltons for peptides and globular proteins, 
and has a bed volume of 15-20ml per gram dry Sephadex 
(Pharmacia Pine Chemicals).
Preparation of the Gel
Since Sephadex G-lOO has a minimum swelling time of 3 
days at room temperature, the gel was allowed to swell for 
this period of time at room temperature, in excess PBS 
which was used as the solvent. The slurry was de-aerated 
before packing the column.
Packing the Column
The gel slurry was packed in a Pharmacia glass column 
with bed dimensions 1 x 30 cm. The column was mounted
vertically and the dead, space under the supporting net and 
in the tubing filled with sterile PBS, which was used as the 
eluant. This was done by injecting the eluant into the 
outlet tubing and pumping it up through the bed support net*, 
y/hen the dead space was properly filled the outlet tubing 
was closed. The gel slurry was then poured carefully 
down the wall of the column, and the column completely filled 
with eluant. An eluant reservoir was connected to the top 
of the column and the last traces of air removed through the 
air vent in the column top piece. To obtain an even 
sedimentation, the flow was started soon after filling the 
column. Approximately 200ml of sterile PBS was allowed to 
pass through the column at a flow rate of 3o2ml per hour, in 
order to stabilise the column bed. A Gilson Minipuls-2 
pump was used to maintain a controlled, steady flow-rate. 
Before starting any experiments, the homogeneity of the bed 
was checked by running through a solution of Blue-Dextran 
2000 (Pharmacia Pine Chemicals) at a concentration of 
2mg per ml. The progress of the zone of this substance 
through the bed was monitored when 0.5ml was loaded onto the 
column, and the flow rate was 3.2ml per hour.
Procedure
A volume of 1.5ml of SN2 was layered onto the bed 
surface and l*6ml fractions collected using a Gilson 
Microcol TDC-80 fraction collector at a flow rate of 3o2ml 
per hour. The protein content of the collected fractions 
was then determined by measuring their absorbance at 230nm, 
Since the gel in a newly packed column usually packs more
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tightly the first time the column is used, this process 
was repeated 3 times, and the fractions obtained from the 
second and third runs retained, and assayed for biological 
activity.
Since more than 20 fractions were retained from each 
experiment, only those fractions containing measurable 
amounts of protein were assayed for biological activity, 
v/ith a fraction containing no protein assayed as a control* 
Other controls included the initial starting material, SN2, 
and PBS which had passed through the column.
Biological activity was measured by injecting mice 
(10 per group) i.p. with 0.1ml of the eluted fractions, and 
measuring their hepatic citrate content 24 hours later. 
Calibrating the Column
The usual method of column calibration (Andrews,1970) 
involves plotting a graph relating the molecular weights 
and gel filtration behaviour of standard compounds* The 
plot of elution volume, Ye, against the logarithm of 
molecular weight is now widely used, and gives a linear 
graph over the middle part of the working range of the 
column.
Reagents
Standard solutions of the following proteins were made
up at a concentration of 2mg per ml of sterile PBS;-
Protein Molecular weight x 10-^
 (daltons)____________
cytochrome-C 12.4
chymotrypsinogen A 24.0
ovalbumin 45,0
BSA 67.0-
aldolase 158.0
Procedure
Each protein solution Was- loaded onto the column and 
"run" separately. 0,5ml of the protein solution was 
loaded onto the column and fractions collected under 
conditions previously described. The protein content of 
each fraction was measured, and an elution profile was 
observed for each protein. The elution volume for each 
protein was measured at the position of half the maximum 
of the peak absorbance of the fractions collected.
The plot of the elution volume, Ye, against the 
logarithm of molecular weight was determined. Linear 
regression was used to determine the line of "best fit" for 
the data points. Prom the graph, the relative molecular 
weight of the biologically active component of SN2 was 
determined,
6 DETERMINATION OP MOLECULAR Y/EIGHT AND HOMOGENEITY 
BY POLYACRYLAMIDE GEL ELECTROPHORESIS 
The molecular weights of proteins can be estimated by 
electrophoresis in polyacrylamide gels. The homogeneity 
of a protein sample during purification procedures can also 
be determined using this technique (Brewer, Pesce and 
Ashworth, 1974; Zahler, 1974).
Reagents for Gel Preparation
(1) 30% acrylamide - 1% methylenebisacrylamide.
(2) 1%N,N,N^,N^ ~ tetramethylenebisacrylamide.
(3) 1 % freshly prepared ammonium persulphate
(4) 0,05% bromophenol blue,
(5) ^mercap to ethanol.
(6) 0,2li phosphate buffer,
(7) Standard protein solutions'.
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The following proteins were used at a concentration of
2mg per ml, dissolved in o/oiM phosphate-0.1%8DS-0.1^P
mercaptoethanol, pH 7.2
Protein Molecular Weight x 10“*^
(daltons)________ _
Insulin 5.75
cytochrome-C 12.4
ovalbumin 45.0
BSA 67.0
Samples subjected to polyacrylamide gel electrophoresis 
were sample number 11 and 12 from gel filtration of SH2, 
These samples were found to be active in increasing hepatic 
citrate levels.
A method permitting the molecular weight determination 
of nanogram amounts of protein was used (Schultz and 
Wassarman, 1977). This method is based on the reaction of 
^H-labelled l-methylaminonapth-alene-5-sulfonyl chloride 
( dansyl chloride) with protein under denaturing
conditions.
Reagents for the Reaction of dansyl chloride
with Protein
(1) 0.05M sodium bicarbonate - 1,4% SDS, pH 9.8.
(2) dansyl chloride, luCi per ul in acetone,
(3) 5ug ovalbumin per ul solution,
(4) 25^ l« trichloroacetic acid, 10% trichloracetic acid,
(5) 95% ethanol,
(6) 0,011:1 phosphate buffer-0.1% SD3-0.1% ^ mercaptoethanol 
solution, pH7.2 (protein solution).
(?) Standard protein solutions, at a concentration of 
2mg per ml, in sterile PBS. The proteins used were
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insulin, cytochrome-C, .ovalbumin, and BSA. Samples were 
fraction number 11 and 12 from gel filtration of SN2 on 
Sephadex G-100.
Method
20ul volumes of standard and sample protein solutions 
were added to 30ul of 0.05M sodium bicarbonate-1.A^LSDS 
solution in Eppindorf microfuge tubes, incubated at 60^0 
for 30 minutes, then 20uCi plf] dansyl chloride (20ul) 
added to the contents of each tube. The reaction mixture 
was then incubated at 37^0 for 90 minutes. lOul of 
ovalbumin was then added to each tube, followed by 90ul 
ice-cold 2 3 % trichloroacetic acid. The pellet was 
precipitated by centrifugation in an Eppindorf-5412 
centrifuge, at 4^0, and then washed seven times with 125ul 
portions of ice-cold 107»trichloroacetic acid. The pellet 
was then solubilised by incubation with 30ul protein 
dissolving solution (g) at 60^0 for 1 hour.
Procedure for Electrophoresis of Samples
A Raven Scientific Electrophoresis Power Supply and 
Pharmacia Gel Electrophoresis Apparatus GS4 were used, and 
siliconised glass tubes of 100mm x 6mm (internal diameter). 
The gel mixture was made up as follows 
5ml Qo21i phosphate buffer-SDS 
3.3ml acrylamide solution 
1ml Temed,
The mixture was degassed and then 0.7ml freshly- 
prepared ammonium persulphate solution added. The gel 
mixture was then pippeted into the glass tubes to a level 
of 80mm, and the gels overlayed with distilled HgO and
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allowed to polymerise .(about 20.minutes).
To each of the standard protein and sample solutions 
was added
lOul 0,05%^^omophenol blue
1 drop glycerol
5ul ^mercaptoethanol.
These mixtures were incubated at 37^0 for 30 minutes, 
and then carefully added to the top of each gel.
Phosphate buffer-SDS, diluted 1:1 with distilled 
HgO, was used to fill the anode and the cathode 
compartments of the electrophoresis apparatus, and the 
gels run at 8 milliamperes per tube for 4 hours. The 
gels were then removed from the tubes, frozen using 
powdered Diy-Kold, and sliced into 1mm sections*
. These sections were then placed into plastic 
scintillation vials and 10ml scintillation fluid added*
The composition of the scintillation fluid was;- 
5g PPO (2,3-diphenyloxazole)
0.5g BIS MSB (l,4-di-(2-methylstyryl)-benzene)
10ml NOS (tissue solubilizer, Amersham)
10ml hyamine hydrochloride 
per litre toluene.
The gel slices were incubated at room temperature for 
48 hours in this mixture (Aloya, 1979), then counted in 
a liquid Scintillation Counter, The distance travelled 
by each protein relative to the boundary of the Bromophenol 
blue marker was measured at the position of maximum counts 
per minute in the gel slices. The Rf value for each 
nrotein was then calculated relative to cytochrome-C,
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whose Rf v/as assumed to be 1, The calculated Rf values 
for each of the standard proteins was plotted against the 
logarithm of their respective molecular weights, and 
linear regression used to determine the line of "best fit" 
for the data points. This standard plot was then used to 
determine the molecular weight of the unknov/n components 
in fractions 11 and 12 and to determine the homogeneity of 
these samples.
(7) MEASUREMENT OR MOUSE SERUM LACTATE 
DEHYDROGENASE LEVELS 
The 5 to 10 fold increase in the activity of LDH 
levels in serum of mice infected with LDV serves as a basis 
for detecting the virus (Notkins, 1965). The increase 
reaches a maximum 96 hours after infection.
Preparation of Serum
'Yhole blood was collected from mice under ether 
anaesthesia* The mice were swabbed down with absolute 
alcohol and a transverse lower abdominal incision made*
The inferior vena cava was rapidly exposed and blood 
extracted from the vein using a wide-bore needle and 1ml 
syringe. By this stage of the experiment the mouse was 
dead.
The collected blood was then carefully transferred 
from the syringe into a glass centrifuge tube and incubated 
for 1 hour at 37^0 to allow the blood to clot. The 
clotted blood was then centrifuged at EOOOgmax* for 10 
minutes and serum removed.
Great care had to be taken throughout this procedure 
to ensure that haemolysis did not take place, since red 
blood cells contain LDH.
56
Measurement of LDH Activity
This procedure was carried but by Dr. D. Thompson, the 
Department of Biochemistry, Gartnavel General Hospital,
Glasgow, The method used was that described by McQueen, 
(1972), The reaction being measured was:- 
Pyruvate •¥ NADH Lactate + NAD
This reaction is catalysed by LDH,
The rate of decrease in absorbance of the sample at 
340nm is a measure of the enzyme activity. An LKB/
Boehringer Kit was used according to the instructions supplied, 
and decreases in absorbance measured in an LKB spectrophoto­
meter. Results were read from the template of the 
spectrophotometer, and are expressed in Units of activity 
per litre,
(8) MEASURMENT OP BIOLOGICAL ACTIVITY IN THE SERID,!
OP TUMOUR-BEARING MICE
This experiment was carried out to determine whether 
the component present in SNl and SN2, responsible for in­
creasing mouse hepatic citrate levels, could be detected 
in the serum of tumour-bearing mice. Serum was collected, 
as previously described, 7 days after the mice had been 
injected vmth 2 x 10^ viable tumour cells. Control 
mouse serum was collected from mice who had been injected 
with sterile PBS,
The collected serum from these 2 groups of mice 
(12 mice per group) was then centrifuged at lC0,000gmax, 
for 4 hours at 4°C and the supernatant retained. This 
procedure was carried out to ensure there were no tumour 
cells nresent in the serum. The supernatant was then
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assayed for ‘biological.activity by injecting 0,1ml into 
normal mice. These mice were killed 24 hours later and 
their hepatic citrate content measured.
( 9 ) MEASURMAENT OF MOUSE BODY TEMPERATURE
McAllister (1978) observed marked decreases in the 
body temperature of mice bearing TLX-5 lymphoma, over the 
7 days of tumour growth. In this study, the body 
temperatures of mice injected with tumour cell-free 
preparations were measured over a period of 9 days and 
compared to the change observed in turnour-bearing mice.
Body temperatures of these mice were measured by 
placing a thermocouple in the inguinal region of each mouse, 
and allowing the reading to stabilise for at least 2 
minutes.
(10) . IN VITRO CULTURE OF TLX-5 LY^lPHOMA CELLS
The tumour cells were cultured to determine whether 
if, after at least 5 passages through tissue culture, the 
"conditioned" cell-free growth medium from the cultured 
cells was biologically active in increasing mouse hepatic 
citrate levels.
Moreover, according to Notkins (1965), LDV can be 
removed from contaminated tumour cells by passaging them 
in culture for at least 4 passages. Consequently, these 
cells were examined by electron microscopy to determine 
whether or not LDV was present. The cells were also 
injected into normal mice i*p* at a concentration of 
2 X 10^ viable cells per 0.1ml to determine whether they 
were still active in increasing hepatic citrate levels.
Method
TLX-5 lymphoma cells were harvested from mice, as 
previously described. It was necessary to separate these 
cells from extraneous tissue debris, and this was done 
using a technique (Paul, 1970) which involved layering the 
cells onto a Picoll-Hypaque solution at room temperature. 
This v/as then spun at 1200r.p,m, for 30 minutes at 25^0 
in an MSE Major centrifuge.
The cells v/ere then v/ashed 3 times with sterile PBS 
to remove traces of Eicoll-Hypaque»at 25^0, and then spun 
at ISOOr.p.m. for 10 minutes. The pellet of cells was 
then resuspended in 10ml of ËPMI-I640 (Gibco Biocult) 
medium and the number of viable cells determined.
A cell count of 0.5-1.0 x 10^ viable cells per ml was 
found.to be adequate for culturing in a 50ml flask 
(Sterilin), The anount of cells seeded was usually 
5x10^, and these were maintained in medium, the 
constituents of which were:-
2ml (10,000 units) pennicillin-streptomycin (Gibco)
5ml of 200 mlT h-glutamine (Plov/)
5ml of 7.5%Nati2G03 (Plow).
This mixture was made up to 500ml with RPMI-I640 and stored 
at 4°0. The cells were maintained at 37^0 in medium 
supplemented with 20% Postal Calf Serum (PCS) and in an 
humidified LEEC CO g incubator, v/ith 95 % air and 5 % CO 2 
passed into the incubator continuously.
Routine passage of cells involved vigorously agitating 
the culture vessel to detach the cells from it and to 
disaggregate clumps of cells. The cells were then spun at
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room temperature for 10 minutes at IGOOr.p.m,, counted as 
before, and passaged in the manner previously described. 
Cell-free "conditioned" growth medium was obtained 
by centrifuging the contents of the culture flask, after 
the cells had been passaged 5 times, at 100,000gmax, for 
4 hours at 4^0. The supernatant was retained and its 
biological activity determined.
(11) ELECTRON MICROSCOPE EXAMINATION OE
TUMOUR CELLS 
Electron microscope examination of in vivo grown 
TLX-5 lymphoma cells was carried out by Mr. J. Parry of 
the University Department of Virology* Examination of 
in vitro grown tumour cells was carried out by Dr. J, 
Sommerville of the Department of Virology, Belvedere 
Hospital, Glasgow.
Method
Elxation and Dehydration
The cells were fixed for 30-60 minutes at room 
temperature in gluteraldehyde (2.3^1 solution in phosphate 
buffer V Mg ^ 4- Ca^ +- sucrose), rinsed twice with PBS, then 
post-fixed for 60 minutes’ in l®fo osmium in phosphate buffer.
The cellular material was then dehydrated for 5 
minutes in each of 30%, 50%, 90% and 95%alcohol. The 
material was finally dehydrated in 100%,alcohol in a 
dessicator two times for 5 minutes and then for 20 minuteso 
Embedding
The following procedure for embedding the material 
was carried out;-
(1) Material was placed in an alcohol-Epon mixture (50;50) 
for 12 hours.
(2) The aloohol-Epon mixture was. changed to a 25:75 
mixture and material retained in this for 6 hours,
(3) The material was finally put in a 100%, Epon for 2 
hours with 2 changes.
Embedded cells were then put in a fresh change of Epon in 
LKB Easy Molds, and placed in an oven for 12 hours at 65^0, 
The material was then sectioned using a Du Pont Diamond 
knife and an LKB Ultramicrotone 1,
The sections were then stained with uranyl acetate 
(50%in alcohol) and lead citrate, and examined using a 
Siemens Elniskopf 101 electron microscope, Kodak 
Electron Image film was used.
Statistical Treatment of Results
Results were calculated from the mean (X) and standard 
deviation (S,D.) of control and test populations using the 
students' unpaired t—test. Tables 1-21 also express students' 
t—values and significant levels for comparisons between test 
population and control group or zero time group.
C H A P T E R  3
R E S U L T S
1. raE EEEECT OP TLX-5 LLliPHOMA CELLS AND
CELL-EREE TUMOUR PREPARATIONS ON MOUSE
HEPATIC CITRATE LEVELS
(i) Storage of Biological Material at -70^0
These studies involved working with biological 
material which is often very labile and susceptible to 
freezing and thawing procedures.. Cell-free ascitic 
fluid (SNl, prepared by the ultracentrifugation of 
ascitic fluid from the peritoneal cavity of TLX-5 
lymphoma bearing mice at 100.OOOgmax. for 4 hours at 
4^0) was required in large volumes in order to 
characterise and isolate the biologically active 
component responsible for increasing mouse hepatic 
citrate levels. Large volumes, of virus-free ascitic 
fluid (SN2, prepared by the ultracentrifugation of SNl 
at 240 jOOOgmax. for 24 hours at 4^C) were also required 
for'these same reasons.
It was therefore thought not only convenient but 
necessary to be able to store these preparations at 
-70^0, but before this was done it was first necessary 
to determine whether SNl and SN2 could be stored 
successfully at -70^C without losing their biological 
activity.
Measurement of the biological activity of SNl and 
SN2 involved injecting mice i,p. with these preparations 
and measuring the hepatic citrate content of these mice 
24 hours after treatment. Eor these results to be
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relevant and to allow for stastical evaluation, it was 
necessary to include at least 6 mice or more in each 
experimental group, Stastical evaluation of the results 
was determined using the Student's unpaired t-test.
In the experiments described in this study it can 
be seen that large numbers of mice were involved, and it 
was therefore thought that if powdered, frozen livers from 
experimental mice could be stored for relatively short 
periods of time without affecting their citrate content, 
this would allow larger numbers of mice to be included in 
each group. Consequently, the effect of storage at -70^0 
on the hepatic citrate content of normal mice was 
investigated,
(a) SNl and 8N2
. Storage of SNl (Table 1) and SN2 (Table 2) at -70^0 
for periods of up to 60 days does not affect their bio­
logical activity, since the preparations 7d.ll still in­
crease hepatic citrate levels in treated mice when stored 
at -70^C for this length of time,
(b) Liver Samples
Storage of frozen, powdered liver at -70^0 does not 
affect liver citrate content to any significant extent, 
as indicated in Table 3. It y/as therefore possible to 
store the frozen, powdered liver samples at -70^0 for 
periods of up to 14 days, when measuring hepatic citrate 
content, without adversely affecting experimental results.
(ii) The Effect on Mouse Henatic Citrate Levels of TLX-3 
L^pnohoma Cells and Tumour Cell-Eree Preparations 
Caiman and McAllister (1975a, 1975b) observed in­
creases in hepatic citrate levels in mice bearing a
variety of experimental tumours, including the TLX-5 
lymphoma. In mice hearing this tumour, increases in 
hepatic citrate content were observed 24 hours after the 
inoculation of 2x10^ tumour cells, and attempts were there­
fore made in this study to reproduce these results, and to 
determine the levels of this metabolite in the livers of 
tumour-bearing animals over the course of tumour grov/th.
Later experiments by McAllister, Soukop and Caiman 
(1977) showed that a cell-free preparation (SNl) of this 
tumour, when injected into normal mice, produced increases 
in hepatic citrate levels similar to the tumour cells.
This observation led to the proposal that a factor or 
factors, present in SNl was. responsible for bringing about 
the metabolite changes measured. These changes in 
hepatic citrate levels described by McAllister, Soukop and 
Caiman (1977) were also observed in this study (Table 4).
Various methods were employed in an attempt to 
characterise the biologically active factor present in SNl. 
These included dialysis, heat-treatment and treatment with 
trypsin. Dialysis indicated whether the factor(s) 
involved was of a low molecular weight (less than 10,000 
daltons), and heat-treatment determined whether it was 
heat-labile. Treatment with trypsin was used to determine 
whether the factor(s) was protein in nature.
During the course of these experiments, mouse spleen, 
thymus and epididymal fat pads were routinely removed and 
weighed in order to determine the effects of the various 
tumour cell-free preparations on the weights of these 
organs.
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Moreover, the effect of-, virus-free ascitic fluid 
(SN2) on hepatic citrate levels was measured, since it was 
possible that ultracentrifugation under the conditions 
previously described might affect the biological activity 
of the preparation by removing the factor(s) involved. 
During the preparation of SN2 proteins: with a molecular 
greater than 450,000 daltons would have pelleted out, and 
if biological activity could still be detected in the 
preparation, this would indicate that the factor(s) 
involved had a molecular weight of less than this. SN2 
was then subjected to dialysis, heat-treatment and trypsin 
treatment.
(a) Hepatic Citrate
Increases in hepatic citrate content of mice bearing 
TLX-5 lymphoma are shown in Table 4. These increases 
were observed as early as 24 hours after the mice were 
inoculated with. 2x10^ viable tumour cells, and could be 
detected throughout the period of tumour growth.
Treatment of the mice with SNl also brought about in­
creases in hepatic citrate levels, which were observed up 
to 5 days after the initial injection of SNl (Table 4).
The data presorted in Table 4 also shows that the 
biological activity of SNl is not affected by dialysis, 
but is totally destroyed by heat-treatment. SN2, as can 
be seen from Table 8, is as active as SNl in producing 
significant increases in hepatic citrate levels, the 
most profound effect being observed 24 hours after 
treatment. Heat-treatment of SN2 (Table 9) and treatment 
with trypsin (Table 10) totally abolishes its biological
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effect, but dialysis hoes not .(Table 9). No biological 
activity could be detected in the resuspended pellet 
obtained during the high speed centrifugation of SNl to 
produce SN2 (Table 9).
(b) Spleen Weight
Tumour-bearing mice showed an increase in spleen 
weight which was detected 24 hours after tumour implant 
(Table 5) and continued throughout the period of tumour 
growth, although at day 7 of tumour growth the observed 
increase did not differ significantly from the control mice, 
who were injected with sterile ?BS. Increases in spleen 
weight were also detected in mice injected with SNl, but 
these increases did not become significant until 3 days 
after treatment and were not observed 7 days after
injection of the preparation (Table 5). Dialysis of SNl 
did not abolish its effect on spleen weight and appears to 
have enhanced this effect, since increases could be 
observed as early as 24 hours after injection. Heat- 
treatment of SNl (Table 5) completely abolishes its 
effect on spleen weight.
Data presented in Table 8 shows that treatment of 
mice with SN2 will also increase spleen weight to the 
same extent as SNl, although increases were not significant 
5 days after treatment but were significant 7 days after 
injection of the preparation,
(c) Thymus '.'/eight
Thymus weight (Table 6) has been shown to decrease 
significantly in mice bearing TLX-5 lymphoma, these 
decreases being observed 24 hours after tumour implant
and continuing throughout, the-period of tumour growth.
However, these decreases were not observed in mice treated 
with SNl, dialysed SNl or heat-treated SNl, and on day 3 
after treatment with SNl thymus weights increased to a 
significant level. Day 5 after treatment with dialysed 
SNl, thymus weights also increased to a significant level. 
These increases then appear to return to normal in mice 
injected with SNl, Mice treated with SN2 do not show any 
significant changes in thymus weight, although small 
decreases in the weight of this organ were observed 3 days 
after treatment with this preparation (Table 8),
(d) Epididymal Eat Pads Weight
Data presented in Table 7 shows that increases in the 
weight of epididymal fat pads can be seen in mice bearing 
the.TDX-5 lymphoma and in mice treated with SNl. These 
changes were observed 24 hours after the mice were treated 
with these preparations, although in tumour-bearing mice 
the increase did not reach a significant level 7 days 
after the inoculation of tumour cells.
Dialysis of SNl abolished its ability to increase 
epididymal fat pad weights, as did heat-treatment. SN2^a\aU3^ 
also had no significant effect on epididymal fat weights, 
although it did increase them slightly as did dialysed 
and heat-treated SNl^ bt*t: rvoh ,
(iii) Dose Response of Mouse Hepatic Citrate levels 
to SN2
It was thought necessary to determine whether the 
biological activity of SN2 was "dose dependant", that is, 
to determine whether hepatic citrate levels were increased
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to a greater extent with the injection of increasing cell 
equivalent concentrations of SH2. Therefore, a sample of 
SN2 was prepared at a cell equivalent concentration of
7
7x10 per ml, and serial dilutions made by a factor of 10 
to an eventual concentration of 7x10^ per ml. Mice were 
then injected with 0.1ml of these preparations and their 
hepatic citrate levels measured. Control mice were 
injected with sterile PBS, and liver citrate content was 
measured 24 hours after all the mice were treated. As can 
be seen from the data presented in Table 11 and in Figure 2, 
a "dose response" to serial dilutions of SN2 was observed, 
but the increases in hepatic citrate levels were not 
significant at a cell equivalent concentration of 7x10^ 
per ml or less. 10 mice were included in each group of 
experimental mice.
Another experiment was then carried out to determine 
the effects of multiple injections of SÏÏ2 on hepatic 
citrate content, A group of 10 mice were injected i.p. 
with 0.1ml of SN2 at a cell equivalent concentration of • 
2x10^ per ml. These mice received a total of 8 injections 
of this preparation; a single injection being given at 
1-hour intervals for a period of 8 hours. Control mice 
were given 8-hourly injections of 0,1ml sterile PBS i.p., 
and hepatic citrate levels measured 24 hours after the final 
injection. A second control group were given 1 injection 
of the SN2 preparation, 0.1ml being injected i.p.
As can be seen from the data presented in Table 12, 
mice given 8x1 hourly injections of SÎT2 do develop an in­
crease in heoatic citrate levels which is significantly
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different from citrate levels.observed in the ?BS treated 
animals. However, this increase in hepatic citrate 
observed in mice given multiple injections of SN2 does not 
differ significantly from the levels measured in mice 
given a single injection, over the period of 24 hours, 
after which the livers were removed,
(iV) Precipitation of SNl and SN2 with Ammonium Sulphate 
Preliminary attempts to fractionate and isolate the 
biologically active factor(s) present in the ascitic fluid 
of tumour-bearing mice, involved using ammonium sulphate 
precipitation of the proteins present in SNl and SN2, To 
determine the degree of purification of these and other 
cell-free tumour preparations, the protein content of each 
was measured, as well as their biological activity.
Results presented in Table 13 show that biological 
activity is present in the 35-65"’le ammonium sulphate 
precipitate of SNl, but not in the 0-35% ammonium sulphate 
precipitate of SN2,
The concentration of protein present in SNl, SN2 and 
the various preparations of SNl and SN2 which have 
previously been described, are shown in Table 14, 
Heat-treatment of SNl decreases its protein content by a 
relatively small amount, whereas dialysis does not appear 
to alter it to any relevant degree. Precipitation of 
SNl with 35-o5% ammonium sulphate results in considerable 
purification of the preparation in terms of protein 
content, without adversely affecting its biological 
activity, although there is some discrepancy in the 
concentration of nrotein measured in this preparation
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depending on the method of measurement used.
Moreover, ultracentrifugation of SHI to produce SN2 
also achieves considerable purification in terms of protein 
content, as well as removing any viruses present in the 
preparation. The resuspended pellet, obtained during 
the preparation of SN2, contains a large amount of protein 
compared with that present in SN2, but it is inactive in 
increasing hepatic citrate levels. Precipitation of 
SN2 with 0-35% ammonium sulphate removes almost all of the 
protein present in SN2, and the redissolved precipitate is 
active in increasing hepatic citrate levels in treated 
mice,
(v) The Effect of Serum from Tumour-Bearing Mice on 
Mouse Hepatic Citrate Levels 
To determine whether the biologically active factor 
present in SHI and SH2 was present in the serum of tumour- 
bearing animals, that is, was a humoral factor, serum was 
collected from tumour-bearing mice and spun at 100,000gmax. 
for 4 hours at 4^0, to remove any cells which may have 
been present. The serum was then injected into normal 
mice i.p., and the hepatic citrate content of these mice 
measured 24 hours later. From the data presented in 
Table 15, hepatic citrate levels were increased to a 
significant extent in these animals, although not to the 
same degree as mice treated with SH2. The biologically 
active factor was therefore present in the serum of TLX-5 
lymphoma bearing mice.
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(vi) The Effect of TEX-5 Lymphoma Cells and Cell-Free
Preparations on Mouse Body Temperature
McAllister (1978) observed significant decreases in 
mouse body temperature in mice bearing the TLX-5 lymphoma, 
over the period of tumour growth. These experiments set 
out to determine whether such an effect could be observed 
in mice treated with a variety of tumour cell-free 
preparations.
Data presented in Table 16 shows that after an initial 
increase in body temperature 24 hours after the inoculation 
of tumour cells, and 3 days later, there is a steady 
decline in body temperature until death of the animals 
occurs.
An initial increase in body temperature was observed 
in mice treated with SNl on day 2 after treatment, but no 
other significant changes were observed until day 7, when 
body temperatures decreased significantly, returning to 
normal on day 8, Heat-treatment of SNl did not abolish 
its effect on initially increasing mouse body temperature, 
but no further changes were observed until day 6 after 
treatment, when another increase was observed, returning 
to normal thereafter. Treatment of mice with dialysed 
SNl also brought about an increase in body temperature, 
which was observed on days 1, 2 and 5 after the initial 
treatment. On day 7 after treatment a decrease in 
mouse body temperature was observed, returning to normal 
on day 8 (Table 16),
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Table 1
storage of SNl at -TpOc
at \cast
Freshly prepared SNl was injected into a group of^  6 mice at a 
cell free equivalent concentration of 2x10^ per Oolml, as 
indicated at Day 0, Mice were killed 24 hours later and 
their liver citrate content assayed. This process was repeated 
at the time intervals indicated, SNl being stored at -70*^ C
between times* Citrate is expressed as umol par gram liver
w e t w e i ^ t *  (V )  i  <AeoiOkt.iov\  ^ a»\<A stc iX ,iS t.itoL
eocyuaW modlt aaaiAst n.î,«\.tS ot <*o-vjO.
LIVER CITRATE CONTENT
Day 0 1 10 28 60
X , Go234 
+ o.oiq îS;gl
,0.246  
— 0,030
. 0.267
- O.OSZ.
4. 0.259 
d: 0.032.
t 1*476 0*841 1.022 1.710
DP 12 12 12 12
P N.S. N.S. N.S. N,S.
Abbreviations % t » test statistic using student's unpaired
t-test.
DP : degree of freedom, z 
P =- statistical ©valuation by student's 
unpaired t-test,
NS = non-sigaificant.
Results were considered NS at p > 0,05
Wheres- number of observations in group 1 (control group)
n^^ number of observations in group 2.
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Table 2 . .
STORAGE OF m 2  AT -70°C
Freshly prepared SN2 was injected into a group of 6 mice 
at a cell-free equivalent concentration of 2x10  ^per 0.1ml, 
as indicated at Day 0. Mice were killed 24 hours later and 
their liver citrate content assayed. This process was 
repeated at the time intervals indicated, S1T2 being stored 
at -70^b between times. Citrate is expressed as umol per 
gram liver wet weighty X i. S.1b .
L rVER CITRATE CON TENT
Day 0 1 10 28 60
X .308 
±  .ova
, .288 
i  ,o5\
. .514 . .516
±  .OSTL
^•512
T .581 ,165 .163 .085
DF 10 10 10 10
P N.S. N.S, N.S. N,S.
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Table 5
storage of liver SAMPLES AT -70^C
Aliquots of frozen, powdered liver, pooled from 10 normal 
mice, were t^en and assayed for liver citrate content at 
the times indicated. The liver was kept at -70®C, 
Citrate levels are expressed as umol per gram liver wet 
weighty ^ t  .
LIVER CITRATE CONTENT
Day 0 2 7 14
"x 0,153 . 0.139 . 0,192 . 0.154
t  o.ow ± 0 .0 1 0 - o.oo<^ t  0.011
t 0,598 0,664 0.267
DF 6 6 .6
P N.S, N.S, N.S.
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Table 4 . .
THE EFFECT OF TLX-5 LYMPHOMA CELLS AMD CELL-FREE 
PRZPAR.1TI0NS ON MCCSE HEPATIC CITRATE LEVELS
At least 6 mice were included in each group. TLX-5 hearing
mice were injected i.p. with 0.1ml of a tumour cell
preparation at 2x10^ viable cells per 0.1ml. Other
experimental animals were treated, as indicated, with a cell
free equivalent concentration of 2x10^ per 0.1ml, Control 
mice were injected i.p, with 0.1ml sterile PBS, Citrate 
levels are expressed as umol per gran liver wet wei^t^ X t  S.D 
Mice were killed, after treatment, at intervals sho^m.
Table 5
THE EFFECT OF TLX-5 L7MPH0MA CELLS AZH) CELL-FREE
p rep a r a t i o n s on MOCTSB SPLEEN V7EIGHT
Mice v/ere treated as indicated in Table 4* Spleen wei^t is 
expressed in grammes.^ x t
Table 6
THE EFFECT OF TLX-5 LYMPHOMA CELLS /JH) CELL-FREE
p r eparations on MŒSE THYMQS VfEIGHT
Mice were treated as indicated in Table 4 . Thymus weight is 
expressed in grammes^ S.Û.
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Dialysis of SHI did not affect its ability to increase hepatic 
citrate content of treated mice at day 1. 3 and 7 after 
treatment. But 5 days after treatment, hepatic citrate 
content of treated mice fell, and did not differ significantly 
from that of the control mice. It did, however, differ 
significantly from the hepatic citrate content of mice 
treated with SHI at day 5 (p^ 0,001),
Tabl.e.A
The E ffe c t  o f TLX-5 L.vmnhcma C e lls  and C e ll-F re e
Preparations on Meuse Hepatic C itra te  Levels
Liver Citrate Content
Days After Injection 1 3 5 7
Controls X 0,141 0.165 0.149 0.155
0 ,014. 0.035 0 .01* 0.035
n VO to to
TLX-5 Bearing Mice X 0.391 0.285 0.252 0.310
4» 0.01,3 0 .04,1 0.o3\
P< 0.001 <0.05 <0,001 <0.001
v\ s % % %
SNl Treated Mice *x 0.312 0.350 0.281 0,169
0,01*3 0 . ov»o O.D3Vf 0,04.0
p <0.001 <0.001 <0.001 N.S.
n % s 8 %
Dialysed Sîîl Treated Mice X 0,249 0.257 0.200 0.250
4* 0.O3S 0,039 0.033
P <0,001 <0,02 N.S. <0,001
lo to 10 ttb
Heat-Treated 83:il Treated Mice T 0.15s 0.153 0.154 0,15c
4" O.D3& O.Olct o,on 0 .01S
P N.S. N.S, N.S. N * S t
n to VO to to
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Table 3
The E ffe c t  o f TLX-5 Lymphona C e lls  and C e ll-F re e
P rep ara tio n  on Meuse Spleen
Spleen Weights
Days After Injection 1 5 5 7
Controls X .C79 .077 0.080 0.114
0310 i. o .o lO o.oov*. O.OW O.otl
TLX-5 Bearing Mice 
n  a S
X .145 .152 .157 
±  ,oiu> ,015 ,0 1 5  
P <0.001 <0.001 <0.001
.156
.0 3%
N.S.
SNl Treated Mice
r\ ? %
X
+
p
0.090
.oiS
N.S.
.142
.O ltj
<0.001
.115
, Otto
<0.01
.114
.030
N.S.
Dialysed SNl Treated Mice X 0.126
±  . ootp
A 3 10  ^ <0.001
0.117
.oil
<0.01
0.105
.ooz
<0.01
.155  
. 013
i'j. s.
Heat-Treated SNl Treated Mice X
±
n -  to ^
0.C79
,oou
N.S.
.076
.005
N.S,
.087
.01H
N.S.
.078
.Otb
N.S.
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Table 6
Tlie E ffe c t  o f TLX-5 Lr/mphcma C e lls  and C e ll-F re e
■ ons on Meuse Thymus Weight
Thymus Wei^t
Days After Injection
Caitrols X .021 ,023 .025 .024
n  = \ o  +  , o o n  . o ' o  ,oo"l éOOif
TLX-5 Bearing Mice X .OCR .006 .007 . 007
± .005 '003 '00% .00%
'^"0 P <0,01 <0.001 <0,001 <0,001
SNl Treated Mice X .051 .060 .051 .020
a -  ,.01% .0 0 5  , 001 .OOU
® P N.S, <0.001 N.S. N.S.
Dialysed SNl Treated Mice X ,024 .025 .052 ,050
_  ± 'OOS .001  .DOS .005
P N.S. N.S, <0.05 <0.05
Heat-Treated SNl Treated Mice X ,019 0.20 .018 .021
t  ,DOU ,O lO  ,0 0 %  ,0O H
V \ 3 \ 0  P N.S. N.S. N.S. N.S.
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Table 7 • "
THE EFFECT OF TLX-5 LYMPHOMA CELLS M D  CELL-FREE 
EXTRACTS ON MOOSE EPHUDYIvÎAL FAT PAD Y/EIGHT
Mice were treated as indicated in Table 4» Fat Pad wei^t 
is expressed in grammes., )( ±  3.0.
Table 8
THE EFFECT OF SN2 ON MOOSE HEPATIC CITRATE LEVEL, 
SPLEEN YŒIGHT, THY^ ÎGS TOIGHT AMD EPIDIDIT.W FAT PAD 
WEIGHT
Six: mice were included in each group. Mice were treated 
with an i.p, injection of 0.1ml of a cell-free equivalent 
concentration of 2x10^ per 0,1ml of 3T2. Mice were killed 
after treatment at intervals sho^m. Controls were injected 
i.p, with 0,1ml sterile PBS.
Table 7
The E ffe c t  o f TLX-5 Lymphona C e lls  and C e ll Free
E x trac ts  on Mouse Epididymal Fat Pad Weight
Fat Pad Weight
Days After Injection 1 5 5 7
Controls X ,494 ,557 .662 •741
A- \ 0 ,%o% .\&u ,x\o
TLX-5 Bearing Mice X 1.089 1.251 1,526 1 .090
3 0 ,3V»Z
p <0.001 <0.001 <0.001 N.S.
SNl Treated Mice X .881 1.501 1 .486 1 ,515
.35V,
n  = & P <0.001 <0.01 <0,001 <0.01
Dialysed SNl Treated Mice X .706 .602 • 546 .950
.2SU .%un .%53
n  - JO p N.S. N.S. N.S. N.S.
Heat-Treated SKI Treated Mice X ,659 .806 0.444 ,531
4* 1 .la's .040
n  -10 P N.S. N • S. N.S. N.S.
80
Table
The E ffe c t  o f SN2 on Mouse Heoatic C it ra te  Level'JL
Spleen Weight, Thymus Weight and Epididymal Pat Pad 
Weight
D a y s  A f t e r  I n j e c t i o n 1 5 5 7
H e p a t i c  C i t r a t e  C o n t r o l s X .1 41 ,165 .149 .155
± . 0 51 .031, . 0 ^ 5 . 0%|
C e n t e n t S H l T r e a t e d  M i c e X .3 49 .520 .275 .149
± .051 .005 . 0 1 5 • O U e
u m o l / g  l i v e r P < 0 ,0 01 < 0 . 0 0 1  ■< 0 . 0 0 1 N . S .
w e t  w t  ^ )T i 3.D
I*
S p l e e n C o n t r o l s X . 0 7 9 .077 0080 .114
. o o l . 0 1 3 .Oil
WT., V h 6. \>. 8 H 2 T r e a t e d  M i c e  X . 1 8 9 .154 ,074 .077
% • o o S • 0 \ 0 , o i l . O U
(e) P<0 .001 <0,001 N.S. <.001
Thymus C o n t r o l s X .021 ,025 • 025 .024
i . 0 0 5 .oil .005 .&04
W T ^  X SN2Treated M i c e X .055 .019 ,0 26 .024
i • bov* . O l o . o o S . o o S
(g) A ï V » p N.S. N.S. N.S, N.S,
Pat-Pads Controls 1 . 4 9 ^ .557 .662 .741
W T .  ^ ± 6 . 0 .
.o4L|1 . 1 4 9 .igrio . Z f O
X .7 06 . 8 6 2 . 6 8 2 ,776
f.-'l
Î
p
.0-11
N . S .
. o m
N . S .
• loV 
N,S,
Ari 
N .S.
gable i
EFFECT OP HEAT-TREATED SN2 DIALYSED BJ2 AND 
RESDSPFNDED @T2 PELLET ON MOTSE HEPATIC 
CITRATE LEVEL
There were at least 6 mice in each group. Mice were
injected i.p, with 0,1ml of a cell-free equivalent
6
concentration of 2x10 per 0.1ml of heat-treated and 
dialysed and of resuspended SN2 pellet. Control 
mice were injected i.p. with O.lcm^ of sterile PBS, 
Hepatic citrate levels were assayed 24 hours after 
injection of mice, and are expressed as umol per gram 
liver wet weight^ X
Controls 
<\« 9
Heat-Treated
SN2
Dialysed
m 2
f\s4
Re suspended
SN2 Pellet 
f\ & &
X 0,168 0,127 0,298 0.176
■+ ,02.4 .03% ,031 .D%b
t 1.585 2.175 0.289
DF 14 15 14
P N.S, <0,05 N.S.
^  The hepatic citrate content of mice treated with dialysed 
SN2, although it is lower than that of mice treated with 
SN2 (Table 8), this difference is not significant.
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Table 10 - .
THE EFFECT OF TRIPSIN TREATED SN2 ON MOUSE 
hepatic CITRATE LEVELS
All preparations were injected I.p, at a cell equivalent 
concentration of 2x10^ per 0,1ml, Control grcup 1 were 
injected i.p, with 0,1ml sterile PBS, Control group 2 
were injected i.p, with 0,1ml of sterile PBS with trypsin 
end trypsin inhibitor, Ccntrol group 5 were injected i,p, 
with 0o3jnl of SN2, The experimental group were injected
i.p. with 0,1ml of SN2 treated with trypsin plus trypsin 
inhibitor. Citrate values are expressed as umol per gram 
liver wet wei^t^ ^  ^  ,
Group Control
1
AC 5
Control
2
A = S
Control 
A= W
Experimental 
A n V»
X O.I69 0,165 ,269 0,162
+ .058 .0 1 4 . OH>8 .0V3
t 0,116 2,802 0.250
DP 8 9 9
P N.S. <0.05 N.S.
The mean citrate value in the experimental group (0.162) also 
differed si^ificantly frcm the mean citrate value of control 
grozp 3 (0 .269) at P <0.01.
Table 11
"DOSB RESPONSE" OP MCaSE HEPATIC CITRATE!
LEVELS TO m 2
Mice were injected i*p* with 0*lml of SN2 at cell eq.uivalent 
concentrations as shown, with 10 mice in each grcup* Control 
mice were injected i*p* with 0,1ml sterile PBS, Hepatic 
citrate content was meamred 24 hcurs after mice had been 
injected. Citrate is expressed as nmol per grsm liver wet 
weight, ? ±  afoup.
0oneentrâtion of SK2 
(cell equivalent per ml)
Hepatic Citrate
X P
Controls 0.16a ± o .O S !
7x1 o5 0.187 ±0,01+0 N.S.
7x10^ 0,204 + O.0T7 N.S.
7x10^ 0,254± 0,03% <0.01
7 x ic f 0,266+0.03't <0.01
7x10^ 0,520 to. Obi» <0,001
Table 12
THE EFFECT OF WLTIPLE INJECTIONS OF SN2 ON 
M0J8E HEPATIC CITRATE LEVELS
Expérimental mice were injected i*p. with 0»3jal of SH2 at a cell 
equivalent concentration of 2x1(7 per ml. These mice received 
8 injections of SN2, a sin^e injection being administered 
hourly. Control group 1 were given 8 injections of 0,1ml sterile 
PBS i*p*, a single injection administered hcurly. Control group 
2 were given a sin^e injection of SN2, 0,1ml being administered
1,p, at a cell equivalent concentration of 2x1 o'^ per ml. 10 mice 
were included in each group, and hepatic citrate levels measured 
24 hours after the final injection. Citrate is expressed as
umol per gran liver wet weight. Results obtained fron Experimental 
group were compared with those obtained from Control groups 1 and
2,
Hepatic Citrate Levels
Control 1 Control 2 Experimental
X 0 .17s 0.256 0.278
± O.OWlk o.dla 0 ,0 3 0
Control 1 t 4.655
P <0.001
Control 2 t 0.848
P N.vSo
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Figure 2
RESPONSE OF MOUSE LIVER CITRATE LEVELS
TO VARIOUS DILUTIONS OF SUPERNATANT 2
o
Sa.
DILUTION FACTOR OF SUPERNATANT 2
Initial cell concentration of ascitic fluid was 7xlo'^/ral. 
Dilutions of Supernatant 2 obtained from this ascitic fluid 
were made with sterile PBS. Control mice injected i.p . 
with sterile PBS had a liver citrate content of 0.168 pmol/g 
liver wet weight. At concentrations lower than 7x10^ cell 
equivalents/ml, when 0 .1ml was injected i.p . into mouse, 
liver citrate levels were not significantly altered from that 
of controls.
Table 15
THE EFFECT OF j&llMŒUJIÆ SQLPHATE FRACTIONATION OP 5Nl 
AND ON TKEIR ijBILITY TO CREASE MOJgE HEPATIC
CITRATE LEVELS
At least 6 mice were included in each group* M c e  were 
injected i.p, with 0,1ml of cell equivalent concentrations of 
2x10^ per 0,1ml of all preparations. Control grcup 1 were 
injected i,p, with 0.1ml of sterile PBS, Control group 2 
were injected i,p, with 0,1ml of untreated SKI. Control 
grop 5 were injected i.p, with 0.1ml untreated SN2,
Experimental group 1 were injected with 0,1ml of the redissolved 
anmonium sulphate precipitate of SNl and experimental 
group '2 with 0,1ml of the redissolved 35-^5% ^ionium 
sulphate precipitate of SNl. The redissolved ammonium
sulphate precipitate of SN2 was injected into mice in experimental, 
group 5# Citrate levels are expressed as umol per gram liver 
wet weighty X -
CONTROL GROJPS EXPEREÆENTAL^GîSrPS
1 2 5
U
1 2
W
5
8
Citrate X .144 ,245 .289 .176 .240 ,267
± .030 ,034 .038p <0.001 <0.001 N.S. <0.001 <0.001
Spleen (g) X .079 .094 .090 .084 .089 .094
4* *OOl *0\5 ,OOVo .00=1 .00% ,oos
P <0,01 N.S. N.S, <0.05 <0o01
Thymus (g) X .026 .029 ,026 .028 .025 .029
■V .OOb .0^ 2. ,oon
p N.S. N.S. N.S, N.S, N.S.
Pat Pads (g) X .555 .745 .671 .558 .568 .698
4 .no .01,8 .134 .148
P <.05 N.S, N.S. N.S. N.S.
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Table 14 _
PROTEIN CONCENTRATION OF B ll AMD SW2 PREPARATIONS
Protein concentrations shown in column 1 were determined by 
the Bradford Method (I976). Preparations wore at a cell 
equivalent concentration of 2x10^ per l.Ctol, Concentrations 
shown in column 2 were determined by absorption of protein at 
23Cnm. Results are expressed as ug per 1ml of sample.
Preparation
Protein (ug/ml) 
Column 1 Column 2
SNl 1777 1858
Heat-Treated SNl 1010 59 .4
Dialysed I3fl 1850 — —
5^(11^ 4)2804 3^1 precipitate 71 61
55-65'^ (N^ 4)28O4 SNl precipitate 41.5 1520
SN2 51 57
Resuspended SN2 Pellet 1660 1742
0-55‘/.(HH4 )2S04 SS2 precipitate 25 14
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Table 15
EFFECT OF SEHJM FROM TDMOJR-BEARING MICE ON 
HEPATIC "CITRATT5 LEVELS
Serum y;as collected fron TLX-5 bearing mice, centrifuged 
at lOO.OOOgnax for 4 hours at 4^8 and 0.1ml injected i.p, 
into 6 mice. Control mice were injected with 0,1ml sterile 
PBS, and a second control group injected i.p. with 0.1ml of 
SN2 at a cell-free equivalent c one en tr action of 2x10^ per 
0.1ml. Hepatic citrate levels were measured 24 hours after 
treatment of mice and are expressed as umol per gram liver 
wet wei^tj t
n_ " _
Control 1 
(PBS)
U
Control 2 
(3T2)
-U .
TLX-5 Bearing 
Mouse Se m m  
S'
X 0.209 0.569 0,510
4 O . o S X 0 .043 0.0*1^
t 4*666 2.447
DF 12 11
p <0.001 <0.05
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Table 16
THE EFFECT OF TLX-5 L W H O M A  CELLS AND ain-ÆOJR 
CELL-FREE PREPARATIONS ON MOUSE BOLT TEt'lPERATnRE.
The body tenperatures of mice injected with TLX-5 lymphoma cells 
and cell-free preparations, as shown, were measured daily for a 
period of 8 days after the initial i.p. injections of 0.1ml of 
cell or cell free equivalent concentrations of 2x10^ per 0.1ml, 
Control mice received 0.1ml sterile PBS i.p.. Body tenperatures 
were measured in ^C\ ^ ^*0,
Day After 1 2 5 4 5 6 7 8
Injection
PBS 
\ - V
X
±
56.7 56.65 57.06
•b8
56.85
*bl
56.96
.as
37.01 57.16 
.44 .4 9
56.96
.SU
TLX-5 X 38.0 
± 3.1S" 
P <0.001
56.85
.,19
N.s;
57.6
.19
N.S.
56.45
,3%
N.S.
55.66
p e
<0.01
55.78 25,92  
.“îS- .11
<0.001 <0.001
Animale
Dead
3T1
U
X
p
57.27
I .n
N.S.
57.76
. 1+5
<0.001
57.56
N.S.
57.56
,31
N.S.
57.21
.32.
N.S.
56.10 36.18
• 4 X  .41» 
N.S, <0.05
56.95
,14
N.S.
Heat- T  
Treated +
s m  “
37.10 
\ .51
57.66 57.20 57.28
,3V+
57.11 57.90 57.70  
#4A .1 4
57.65
,3 3
rvcU p N.S. <0.01 N.S. N.S. N.S. <0.02 N.S. N.S.
Dialysed X 37.5 57.65 
SHI i  .31 
p<0.05 <0.01
56.71
.38
N.S,
57.25
.43
N.S.
57.81
.33
<0.01
56.5 56.55  
,2.x .<43
N.S. <0.05
56.46
.3%.
N.S.
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2. THE PURIFICATION AND MOLECULAH WEIGHT
DETERMINATION OF THE BIOLOGICALLY ACTIVE 
COMPONENT OF TlX-5 LYMPHOMA QBLL-FREE 'ASCITIC 
FLUID
G-el filtration and gel electrophoresis are useful 
techniques for the purification and molecular weight 
determination of unknown compounds of biological origin.
G-el filtration is particularly useful in that the biological 
activity of substances eluted from the gels can be 
determined, in this case by injecting mice v/ith the 
eluted fractions and measuring their hepatic citrate 
content. Unfortunately, the biological activity of 
substances subjected to electrophoresis in polyacrylamide 
gels could not be determined in this case, since it was 
not possible to elute these substances from the gels. 
However, this method was useful in determining the 
homogeneity of biologically active fractions obtained 
from the gel filtration of SN2, and in determining the 
relative molecular weight of the biologically active 
component. These methods have been described in 
detail in Chapter 2 of this thesis.
(a) Gel Filtration of SN2 on Sephadex G—100
Since SN2 represented a relatively pure tumour cell- 
free preparation in terms of protein content, and was free 
of viral contamination, it was used in these experiments.
The elution profile of SN2 on Sephadex G-lOO is shown in 
Figure 3. As fractions were eluted from the gel their 
absorbance at 230nm was measured and plotted against
qi
^  Table 18 shows that the protein content of the eluted
fractions is less than that of the starting material, SN2 
Fractions 11 and 12 had a relatively high protein content and 
were active in increasing the hepatic citrate content of 
treated mice (Table 17). Fraction 4, although having a 
high protein content relative to the other fractions, was 
inactive in increasing mouse hepatic citrate levels (Table 17).
elution volume. The biological activity of the eluted 
fractions containing protein v/as measured and is shown in 
Table 17. The protein content of these eluted fractions, 
measured by their absorbance at 230nm, is shov/n in Table
18 f
Determination of the relative molecular weights of 
the eluted fractions in which biological activity was 
detected (fraction numbers.11 and 12) involved comparing 
the elution profile of the unknowns with that of proteins 
of a known molecular weight. The elution profiles of 
cytochrome-0 (Figure 4), ovalbumin (Figure 5), 
chymotrypsinogen (Figure 6), aldolase (Figure 7) and BSA 
(Figure S) are shown. The log of the molecular weights 
of thesa proteins was plotted against their respective 
elution volumes (Figure 9) and linear regression used to 
determine the line of "best fit" for the data points.
This standard graph was then used to determine the 
relative molecular weight of the biologically active 
component of SN2 present in fractions 11 and 12, which was 
found to be between 6948 -7585 daltons.
(b) Gel Electro-phoresis
Electrophoresis of the biologically active fractions 
obtained from gel filtration of SN2 on Sephadex G-lOO was 
carried out on polyacrylamide gels. The relative 
mobility of the active factor, as determined by its peak 
of counts per minute, that is, the extent of reaction of
5Hj dansyl
chloride, were compared with the mobility of ovalbumin and 
3SA (Figure 10) and cytochrome-C and insulin (Figure 11),
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The insulin used was bovine insulin (Sigma).
It may be, however, that insulin target cells in the mouse do 
not respond when bovine insulin is used. Therefore further
experiments, using insulin from different sources, would be 
necessary before insulin could be excluded as the active 
protein factor. Moreover, the concentration of active 
insulin injected into the mice may have been very low, and 
future experiments might involve using greater concentrations 
of insulin.
The Rf values of each of the-standard proteins relative 
to the mobility of cytochrome-0 in the gels was plotted 
against the log of their respective molecular weights 
(Figure 14) and linear regression used to find the line 
of "best fit" for the data points. Fractions 11 
(Figure 12) and 12 (Figure 13) were shown to contain 2 
peaks of activity in identical positions within the gel, 
and the relative mobility of these proteins within the
gel was: used to determine their molecular weights. The
molecular weights, of the proteins present, as determined 
from the standard graph, were 103,276 and 6886 daltons, 
respectively.
(c) The Effect of Insulin on Mouse Hepatic Citrate Levels
Since the low molecular weight protein of the bio­
logically active component of SH2 had a molecular weight 
similar to that of insulin, which has a molecular weight 
of 5730 daltons, it was decided to measure the effect of 
insulin, if any, on the hepatic citrate levels of normal 
mice. Moreover, McAllister (1978) found decreases in 
plasma glucose levels of TLZ-5 lymphoma bearing mice, 
but since he did not measure plasma insulin, he could not
attribute these low levels of glucose to increased levels
¥r
of circulating insulin.
However, data shown in Table 19 shows that when 
insulin is injected i.p. into normal mice at a 
concentration of protein similar to that injected when 
mice were treated with fraction 11 and 12 from the gel 
filtration of SH2, this has no effect on hepatic citrate 
levels. This biologically active factor does not appear 
xo be rnsumrn.
a?,
Table 17 . .
EFFECT OF FRACTIONS ELUTED FROM SEPHADEX 
G-1.00 COLUMN ON MOTSE HEPATIC CITRATE LEYEI^ S
1,5ml of SN2 at a cell equivalent concentration of SxlO^ per 
1ml was used as starting material. Fractions were collected 
every 50 minutes from the Sephadex G-lOO column at a rate of 
5,2ml per hour, 0,1ml of the fractiens indicated below were 
injected i,p, into groups of 10 mice, and hepatic citrate levels 
assayed 24 hours after injection. Control mice received 0,1ml 
of PBS buffer which had passed throu^ the column. Citrate is 
expressed as umol per gram liver wet wei^itjA .Mice injected 
with SN2 received 0,lcm^ of a cell-free equivalent concentration 
of 8x10^ per O.lcm^.
Fraction No. Elution
Volume
cm^
Hepatic Citrate
X ?
4 6,4 0.159
3  o.ObH
N.S.
9 14.4 0,085 
±  0.023
N.S.
10 16,0 0,160 
± O.O&Z
N.S.
11 17 .6 0.265
± 0.041
<0,001
12 19 .2 0,245
dt 0 .0 leS
<0.05
15 20,8 0.205
± 0.053
N.S.
20 52.0 0,140
0 .0 I4
N.S,
Si 2 0.242
± 0.023
<0,001
Controls * — 0,140  
i O.owl.
QA
Table 18  ^ : .
PROTEIN CONTENT OF S^2 FRACTIONS ELUTED FROM 
SEPHADEX 0-100 COLÏÏM
Protein concentrations were determined by measuring the 
absorbance of the protein at 250nm, Figures shown are 
for fractions collected when the cell equivalent concentration 
of the starting material was 2x10^ per 0,1ml and are expressed
as ug per Iml. This experiment was carried out in duplicate
and the results sho?m are the means of t w o  experiments.
Fraction Elution Protein Content
Number Volume (cm5) ug/an^
4 6,4 9.55
9 14.4 0.99
10 16,0 2,61
11 17.6 8 .52
12 19 .2 10.52
15 20.8 2.74
20 52 .0 1.09
SN2 — — 57.0
9;
Table 19
EFFECT OF DTglTLIN ON MOTSE HEPATIC CITRATE LEVELS
A group of 6 mice were injected i.p* with 0.1ml of insulin 
at a concentration of 9 insulin per 0.1ml of sterile 
PBS. Control mice were injected i.p. with 0.1ml sterile 
PBS.
Controls Insulin
Treated
X 0.209 0.282
± O.01+.3 O.bi+I
t 1.925
DF 10
P N.S.
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Fifflire 3
ELUTION PROFILE SUPERNATANT 2
2'On
o
12-
LU
6*4 9-6 12-8
Elution Volume (ml)
3*2 22*16*0 19*2
Sample volume was 1,5ml. SN2 was loaded onto the 
column of Sephadex G-lOO at a cell•'equivalent concentration 
of 8x10^ per ml. Bed dimensions were 1x50 cm. Blow - 
rate was 5,2ml per hour. Fractions were collected at 
50 minute intervals, and their absorbances at 250nm 
recorded. The eluant was sterile PBS.
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ELUTION PROFILE CYTOCHROME C
2 On
LU
6*4 9*6 12*8 16*0 192
Elution Volume (ml)
3*2 22*4
Saxnple volume of cytochrome-C v/as 0.5ml, loaded onto 
a Sephadex G—100 column at a concentration of 2mg per
m. Bed dimensions were 1x50 cm. Blow rate was 3.2ml
per hour. fractions were collected at 30 minute 
intervals, and their absorbance at 230 nm recorded. 
The eluant was sterile BBS.
^8
Figure 5
ELUTION PROFILE OVALBUMIN
2 On
00
•5 0 8-
lU
G'4-
9^ 6
Elution Volume(ml)
12-8 160 192 22-46 432
Sample volume of ovalbumin was 0.5ml loaded onto a 
Sephadex 0-100 column at a concentration of 2mg per ml. 
Bed dimensions were 1x30 cm. Flow rate was 3,2ml per 
hour. Fractions were collected at 30 minute intervals, 
and their absorbance at 230nm recorded. The eluant was 
sterile PBS.
Fi^re 6
ELUTION PROFILE CHYMOTRYPSINOGEN A
V6"
•g 0  8-
LU
3-2 9*6 12-8 160 19*2 22-
Elution Volume (ml)
6*4
Sample volume of chymotrypsinogen was 0,5ml loaded 
onto a Sephadex G—100 column at a concentration of 2mg 
per ml. Bed dimensions were 1x50 om, Blow rate was 
5,2ml per hour. Fractions were collected at 50 minute 
intervals, and their absorbance at 250nm recorded*
The eluant was sterile BBS,
1 0 0
PifflAre 7
ELUTION PROFILE ALDOLASE
1'6~
CO
1-2 »
0*4
96 12-8 16-0 19-2 22
Elution Volume (ml)
6*43*2 4
Sajnple volume of aldolase was 0.5ml loaded onto a 
Sephadex 0-100 column at a concentration of 2mg per ml. 
Bed dimensions were 1x30 cm. Plow rate was 3o2ml per 
hour. fractions were collected at 30 minute intervals 
and their absorbance at 230nrn recorded. The eluant was 
sterile PBS,
figure S
ELUTION PROFILE BOVINE SERUM ALBUMIN
2-0
1*6 -
co
cs ].2»
•g 0 8-
UJ
0 *4 -
3*2 64 9-6 12*8 16-0 19-2 22-4
Elution Volume (ml)
Sajnple volume of BSA v/as 0,5ml loaded onto a Sephadex 
0-100 at a concentration of 2mg per ml. Bed dimensions 
were 1x50 cm. Plow rate was 5.2ml per hour, Fractions 
were collected at 50 minute intervals, and their 
absorbance at 250nm recorded. The eluant was sterile 
PBS.
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iPlRure 9
20n
18-
16-
14-
Ê
% u
I
I ®
T2-
10-
6-
2 -
;V;Un known 
\ M.W = 7585-V U daltons
Cytochrome C
Chymotrypsinogen A
BSAi
Aldolase
Log Molecular Weight
The elution volumes of the various proteins determined 
from their elution profiles on Sephadex G--1C0 v/as 
plotted against the log of their respective molecular 
weights. This standard graph was used to determine the 
molecular weight of the unknown protein in biologically 
active fractions.
F i ^ r e  10
Mobility of Ovalbumin and BSA in Polyacrylamide 
Gels
BSA
3 -
0
1 2-
ÛLV
Ovalbumin
1005 0
Movement of Proteins Relative to Bromophenol Blue
Samples were electrophoresed in 1 C polyacrylamide
gels for 4 hours at 8 milliamperes per tube. Gel
dimensions were BOrnmxGmin (internal diameter).
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Plaire 11
Mobility of Cytochrome-0 and Insulin-Polyaorylamide 
G-els
Cytochrome C
8“!
6“
Insulin
5-
£
8-
2 -
50 100
Movement of Proteins Relative to Bromophenol Blue
Samples were electrophoresed in 10">(^ polyaoi^^lamide gels 
for 4 hours at 8 milliamperes per tube. lei dimensions
were 80mmx6mm (internal diameter).
1 0 5
Figure 12
Mobility of protein in Fraction 11 (from G-el Filtration 
of SF2) in Polyacrylamide Gels
CO
o
lib
11a
1005 0
Movement of Proteins Relative to Bromophenol Blue
Samples were electrophoresed in 10*|, polya.crylamide gels
for 4 hours at 8 milliamperes per tube. G-el dimensions
were 80mmx6mm (internal diameter).
1 0 6
Figure 13
Mobility of Protein in Fraction 12 (Prom G-el Filtration 
of SN2) in Polyacrylamide G-els
5-1
12b
o_
12a
1005 0
Movement of Proteins Relative to Bromophenol Blue
Samples were electrophoresed in 10®(^, polyacrylamide gels
for 4 hours at 8 milliamperes per tube, G-el dimensions
were BOmmxGmm (internal diameter).
1 0 7
F i ^ r e  14
Rf of Standard Proteins versus Log Molecular Weight
®  Unknown (b)
A m ,W = 6886-.^ i daitons
Insulin ® y i ^ h r o m e  C
\  ®Ovalbumin
>  1 0 -
0-5
®  Unknown (a)
\  M.W = 103,276 doltons
BSA®
Log Molecular Weight
The Rf values of standard proteins determined by their 
mobility in 10®/o polyacrylamide gels was plotted against 
the log of their respective molecular weights. This 
standard graph was used to determine the molecular weights 
of the unknown proteins in fractionsll and 12 obtained 
from gel filtration of SÎ-I2*
3. STUDIES ON TH5 VIRAI: -CONTAMINATION OP
TLX-3 LBIPHQMA
As has previously been stated, experimental tumour 
systems are frequently contaminated, not only with 
viruses but with bacteria (Notkins, 1963; Kampschmidt 
and Schultz, 1969), The most frequent contaminant of 
murine tumours is the lactate dehydrogenase .virus (XDV), 
v/hose most profound effect is an elevation of plasma or 
serum lactate dehydrogenase (IDE) activity of infected 
mice. This elevation of IDE activity reaches a peak 
96 hours after infection v/ith the virus (Notkins, 1965) 
and serves as one of the methods of detection of the 
presence of the virus. Another method v/hich can be used 
to detect the presence of this virus involves the 
examination of tumour cells using electron microscopy. 
These 2 methods of detection were used in this study to 
determine whether TLX-5 lymphoma cells were contaminated 
with this virus.
One method which can be used to eliminate this viral 
agent from contaminated tumours is by passaging the tumour 
cells tiirough tissue culture several times. Thus the 
TLX-5 lymphoma cells were grown in tissue culture for at 
least 5 passages and injected into normal mice to 
determine whether they were still active in increasing 
hepatic citrate levels.
The possibility that the increase in hepatic citrate 
levels observed in tumour-bearing mice was due to the 
oresence of viral contaminants of the tumour cells and
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not to the presence of the tumour had to be investigated. 
Passage of the tumour cells through tissue culture also 
would be able to help distinguish whether the active 
factor purified from cell-free ascitic fluid was of host or 
tumour cell origin. If biological activity could be 
detected in the conditioned" cell-free growth medium from 
the tumour cells this would indicate that the factor was 
initially of tumour cell origin.
Moreover, ultracentrifugation of SNl at 240,000gmax, 
for 24 hours at 4^0 would have the effect of removing 
viral particles from the preparation. Thus SW2 is a 
virus-free preparation,
(a) Serum IDE Activity
Serum was collected from mice injected with tumour 
cells, and with SN2, Control mice were injected with 
s.terile PBS. Serum was collected from these mice 96 
hours after the mice had been treated. The IDE activity 
of the collected serum is shov/n in Table 20. It can be 
seen from these results that activity of this enzyme is 
increased not only in tumour-bearing mice but in mice 
treated with the virus-free preparations, SE2.
(b) The Effect of In Vitro Grown TLX-3 Lymphoma Cells and 
Cell-Pree Growth Medium on Mouse Eepatic Citrate 
Levels
Data presented in Table 21 shows that in vitro grown 
TLX-5 cells passaged through tissue culture for 5 passages 
was effective in increasing mouse hepatic citrate levels in 
treated mice. The "conditioned" cell-free medium from 
these cultured cells was also effective in increasing
110
hepatic citrate content. Inspection of these in vitro 
grown cells using a light microscope did not reveal 
the presence of host cells in the preparation, hut the 
possibility still exists that host cells, particularly 
lymphocytes, are present in the cultured cells in very 
small amounts. Nevertheless, since the cell-free growth 
medium from these cells was effective in increasing 
hepatic citrate content, this v/as thought to indicate 
that the biologically active factor was primarily of 
tumour cell origin since it was present at a concentration 
high enough to affect liver citrate levels. -
(c) Electron Microscope Examination of In Vivo and In 
Vitro Grown TLX-5 lymphoma Oells
Electron microscope examination of in vivo grown 
TLX-5 lymphoma cells revealed the presence of virus 
particles. These virus; particles are shown in Plates 1, 5 
and 4, and are indicated by the arrows. They are rounded 
or elliptical particles, the rounded particles having an 
average diameter of 70mu, and the elliptical particles an 
average length of 70.07muo Plate 1  shows a calibration 
photograph for Plate 1.
Electron microscope examination of in vitro grown 
TLX-5 lymphoma cells, grovrn in tissue culture for 5 
passages, did not reveal the presence of any viral particles.
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Table 20
MOJSE SEEJM lactate DEHYDR0G5HESS
The seivim LDH activity of mice treated as indicated was 
measured, Seium was collected 96 hcurs after mice had 
been treated. All mice were injected i.p, Y^ith 0.1ml of 
a cell or cell equivalent concentration of 2x10^ per 0.1ml, 
Ccsitrol mice received 0.1ml sterile PBS. Activity of LDH 
is expressed as tT per l i t r e ^ ^
LDH ACTIVITY
Controls TLX-5
Bearing Mice
SN2
Treated Mice
X 1637.5 5517.1 4128.0
15 y n
t 11,021 8.297
DP 15 11
P 40.001 <0.001
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Table 21 ;
THE EFFECT OF DT VITRO GROWN TLX-5 LYMPHOMA CELLS 
BD "CŒDITIONED" CULIUKB ON ÎOTSE HEPATIC
CITRjyTE LEVELS
There were at least 6 mice in each group. Control groip 1 
were injected i,p. with 0.1ml of culture medium in which no 
cells had been grown* Experimental group 1 had been 
injected i.p. with 0.1ml of a cell concentration of 1x10^  
viable cells per l.Cml of TLX-5 cells gro\?n in vitro. 
Experimental grcup 2 received 0.1ml of a cell concentration 
of 1x10^  viable cells per 3ml of in vivo grown TLX-5 cells, 
harvested after a fifth passage through tissue culture. 
Experimental group 5 received 0.1ml of the cell-free 
conditioned culture medium from the in vitro grov/n cells* 
Citrate levels are in umol per gram liver wet weight.^  X "h ib.
Control
Grcup
Experimental
1
Experimental
2
Experimental
5
X 0.181 0.267 .507 . 0.267
± 0.020 O.OSZ. .O"60 O .0X1
T 5.226 4,825 5.226
DF 14 12 14
P <0.01 <0.001 <0.01
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Plate 1 In vivo grown TLX-5 lymphonia cell preparation. 
Pinal magnification 13,745%. Virus particles are indicated 
by the arrows.
Ill'
e 7
; ,»Cl
Plate 3 In vivo grovm TLX-5 Lymphoma cell preparation. 
Pinal magnification 45,200%. Virus particles are 
indicated by the arrows.
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Plate 4 In vivo grown TIX-5 l^vnphoma cell preparation 
Pinal magnification 9750%. Virus particles are indicated
by the arrows.
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CHAPTER 4
D I S C U S S I O N
(i) Hepatic Citrate Levels
Haven, Randall and Bioor (1949) showed that in rate
bearing the Walker 256 carcinosarcoma the citrate content
of liver, kidney and spleen was higher than that of control
animals. In later studies, Caiman and McAllister (1975(a),
1975(b)) observed significant increases in the hepatic
citrate content of mice bearing the TLX-5 lymphoma,
Sarcoma-180 and C5H mammary tumours. In the case of
TLX-5 lymphoma bearing mice, these changes were observed as
early as 24 hours after the injection of 2x10^ viable
tumour cells. This was thought to indicate that products
present in the ascitic fluid of tumour-bearing mice were
to
responsible, as this, was found not^be an allogeneic effect. 
Later experiments (McAllister, Soukop and Caiman, 1976; 
McAllister, Soukop and Caiman, 1977) justified this 
proposal, since these early changes in hepatic citrate 
content were observed in mice treated with a cell-free 
ascitic fluid preparation of TLX-5 lymphoma (SNl).
Data presented in this study showing changes in 
hepatic citrate content, at 2 day intervals over a 7 day 
period, in mice injected with TLX-5 lymphoma cells or SNl, 
shows that these changes follow a similar pattern to those 
described by Caiman and McAllister (1975(a), 1975(b)) and 
McAllister, Soukop and Caiman (1976), suggesting that a
factor or factors present in SNl are involved in the 
aetiology of these changes.
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Experiments were then carried out to define the 
nature of the biologically active component of SNl, and to 
determine whether one factor or more was responsible for 
this biological activity. SNl v/as subjected to dialysis, 
which was found to have no effect on its ability to in­
crease hepatic citrate levels. Heat-treatment, however, 
completely destroyed its biological activity. These 
results indicate that the biologically active component(s) 
of SNl is heat-labile, and may have a molecular v/eight 
greater than 10,000 daitons.
It was then necessary to determine whether this 
biologically active component(s) was primarily of tumour 
or host origin, since it was possible that it may have 
been produced by the host in response to the presence of 
the growing tumour. The TLX-5 cells were grown in vitro 
for several passages, and a cell-free preparation of 
"conditioned" growth medium prepared. Mice injected with 
this preparation showed changes in hepatic citrate content 
similar to those of mice injected with SNl, These 
results indicate that this biologically active factor(s) 
is present in the "conditioned" growth medium from the 
TLX-5 lymphoma cells and is probably primarily of tumour 
origin. Examination of the in vitro grov/n tumour cells 
using a light microscope did not reveal the presence of 
host cells in the preparation, but the possibility remains 
that there may have been host lymphocytes present in the 
preparation, in very low concentrations.
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Considerable purification in terms of protein 
content was obtained upon high speed centrifugation of 
SNl at 240,000gmax for 24 hours (to give SN2), and 
upon precipitation of SNl with ammonium sulphate.
Both of these purification procedures did not alter the 
biological activity of the preparation, and since 
ultracentrifugation results in a virus-free preparation, 
subsequent studies were carried out using SN2. Large 
volumes of SNl and SN2 were required for these and 
other purification procedures, and it was possible to 
store SNl and SN2 at -70^0 for periods of up to 60 days 
without affecting their biological activity.
Dialysis of SN2 did not affect its biological 
activity, but heat-treatment did. Y/hen SN2 was treated 
with trypsin its biological activity was completely 
destroyed, indicating that the biologically active 
factor(s) involved is protein in nature. The effect of 
SN2 on hepatic citrate levels was also shown to be 
concentration dependant. Since the active factor(s) 
was not removed by dialysis or by ultracentrifugation 
under the conditions described, it was thought likely 
to have a molecular weight in the range 10,000-45,500 
daitons.
G-el filtration is a valuable technique for the 
estimation of the molecular weights of unknown 
compounds (Andrews, 1970) particularly proteins, and 
can be applied to the isolation and purification of
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proteins. Sephadex is p.articularly useful for the 
chromatography of substances of biological origin, 
which are often very labile. In gel filtration 
quantitative yields are obtained as there is no ir­
reversible retention of small amounts of substances on 
the column, and it is therefore useful for analytical 
purposes. The choice of the appropriate Sephadex 
type depends on the molecular size of the substances to 
be separated, since each Sephadex type fractionates 
within a particular molecular weight range determined 
by the degree of swelling of the gel.
Molecules with a molecular weight in the range 
10,000-45,500 daitons can be separated upon columns 
of Sephadex G-lOO, This Sephadex type has a molecular 
weight fractionation range between 4,000-150,000 
daitons for peptides and globular proteins (Andrews, 
1970), Fractions eluted from a Sephadex 0-100 column 
were tested for biological activity, and activity was 
detected in fractions in which molecules of a relative 
molecular weight of 6948.6-7587.7 daitons would be 
eluted.
Moreover, the molecular weight of a protein can 
also be estimated by electrophoresis in polyacrylamide 
gels. The homogeneity of protein samples during 
purification procedures can also be determined using 
this technique. The advantages of using this method 
are that it can rapidly separate complex mixtures of 
protein with high resolution, and requires only a small
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amount of protein. .The main.factors which effect 
separation are time of electrophoresis, the 
concentration of acrylamide in the gels, and the 
sample volume. Short electrophoresis times and high 
acrylamide concentrations (lO^ jo or greater) favour the 
separation of low molecular weight compounds.
Biologically active fractions, obtained from the 
gel filtration of SN2, were subjected to polyacrylamide 
gel electrophoresis under the conditions described in 
Chapter 2, The mobility of the components of these 
fractions within the gel was found to be identical.
These fractions were found to contain 2 main components, 
one with a relative molecular weight of 688605 daitons, 
the other with a relative molecular weight of 103,276 
daitons. The presence of this high molecular weight 
component in these fractions presents a dilemma, since 
molecules of this size would not have eluted from the 
Sephadex G-lOO column at the same point as the 688605 
daitons component, nor would it be present in SN2, It 
is thought that this molecule may be present due to the 
contamination of glassware during the purification 
procedures, or may be ovalbumin which was introduced as 
a "carrier-protein" during the dansyl chloride
reaction of the proteins. The low molecular weight 
component of 688605 daitons is thought to be the 
biologically active component of SN2.
Moreover, biological activity could also be detected 
in the serum of turnour-bearing mice, indicating that
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this factor is a humoral factor. Since this factor 
has a molecular weight similar to that df insulin, 
normal mice were treated with insulin and their 
hepatic citrate conthnt measured. Insulin was found 
to have no effect on hepatic citrate levels, but it is 
of interest that marked decreases in serum insulin 
have been reported in rats bearing Walker 256 
carcinosarcoma, accompanied by decreases in serum 
glucose levels (G-oodlad, Mitchell, McPhail and Clark, 
1975)• It was concluded by these workers that these 
decreases in serum insulin and glucose reflected the 
general disturbances of energy metabolism in the host 
associated with tumour growth.
Although these results show that there is a factor 
present in the ascitic fluid and sera of turnour-bearing 
mice, responsible for increasing hepatic citrate levels, 
and that this factor is heat-labile, probably primarily 
of tumour origin, protein in nature with a molecular 
weight between 6,800-7,600 daitons, these results give 
no insight into the mechanisms underlying the production 
of this metabolic abnormality.
These observed changes in hepatic citrate content 
are opposite to those found in animals under conditions 
of forced gluconeogenesis (Wieland, 1966; Start and 
Newsholme, 1966) although McAllister, Soukop and 
Oalman (l976, 1977) argue that an accumulation of 
citrate in the livers of tumour-bearing mice would 
inhibit chosohofructokinase, since citrate is one Oj.
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several modifiers of the enzyme (Start and Newsholme, 
1970). This would result in a reduction of the 
glycolytic flux in the liver and favour gluconeogenesis, 
since phosphofructokinase is a rate-limiting enzyme in 
glycolysis. This mechanism, however, does not appear 
to regulate gluconeogenesis in the liver of normal 
animals, since under gluconeogenic conditions the 
hepatic citrate content decreases (Start and Newsholme, 
1968; Herrera and Frienkel, 1968),
(ii) Spleen
Hypertrophy of the spleen of tumour-bearing 
animals has been frequently observed (Stewart and Begg, 
1953; Konda and Smith, 1973). Nakahara and Fukuoka 
(1958) and Adams and McCoy (1959) showed that rapid 
enlargement of the spleen occurred in mice injected 
with "toxohormone", Injection of cell-free ascitic 
fluid from TLX-5 lymphoma bearing mice (McAllister, 
Soukop and Oalman, 1'977) was also shown to induce 
spleen hypertrophy.
It has also been shovm in this study that the 
spleen weight of TLX-5 lymphoma bearing mice and mice 
injected v/ith SNl increases significantly. Dialysis 
of SNl does not affect its ability to increase the 
spleen weights of treated mice, but heat-treated SNl 
will not produce this effect. SN2 treated mice also 
show an increase in spleen weight,
Konda and Smith (1973) were of the opinion that 
hypertrophy of the spleen v/as due to the immune 
response, and presented evidence shov/ing that the
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functional, immunologically competent cells of the 
spleen were increased during turnour-bearing. They 
also suggested that tumour cell products may be involved 
in producing these effects.
It would appear that a factor or factors present in 
SNl, which is non-dialysable, heat labile and present in 
the high speed supernatant of SNl and in the 35-65®|o 
ammonium sulphate precipitate, is responsible for 
increasing spleen weight. From this data the molecular 
weight of this factor or factors is between 10,000- 
45,500 daitons, but no further investigations into the 
nature of the factor or factors involved was carried out.
(iii) Thymus
Thymic atrophy is a frequent finding in tumour- 
bearers, and Konda and Smith (1973) showed a decrease 
in thymus cell numbers over the course of tumour growth. 
The functional, immunologically competent cells of the 
thymus, as well as the spleen, were also shown to be 
increased during tumour-bearing. Ertl (1973) showed 
that in rats bearing the Walker 256 carcinosarcoma 
commencement of thymic atrophy was related to the onset 
of progressive cachexia, and these results were 
confirmed by McAllister, Soukop and Caiman (1976,
1977).
Moreover, Nakahara (1952) demonstrated thymus 
involution in animals injected with "toxohormone", but 
in this study thymus involution was not seen in mice 
injected with SNl although it could be seen in tumour- 
bearing mice. Decreases in thymus weight were detected
125
in mice injected with SN2, hut these changes did not 
reach a significant level.
(iv) Enididymal Fat Pads
Haven, Bloor and Randall (1949) showed that in rats 
hearing the walker 256 carcinosarcoma carcass lipids 
varied inversely with the size of the tumour, but 
McAllister, Soukop and Caiman (1976) did not observe a 
loss of carcass lipid in mice bearing the TLX-5 
lymphoma. They did observe, however, increases in the 
epididymal fat pad weight of these mice during the 
course of tumour growth.
Data presented herein confirms the results of 
McAllister, Soukop and Caiman (1976) and shows that in 
TLX-5 lymphoma-bearing mice and mice injected with SNl, 
significant increases in epididymal fat pad weight does 
occur. Dialysis and heat-treatment of SNl destroys its 
activity in producing these changes. Also, mice 
injected with SN2 do not show any significant changes 
in epididymal fat pad weight. These results indicate 
that the factor or factor(s) present in SNl responsible 
for bringing about these changes is heat-labile, and 
removed by ultracentrifugation.
From these results it would appear that there are 
several different factors present in the cell-free 
ascitic fluid from TLX-5 lymphoma-bearing mice 
responsible for bringing about the observed systemic 
effects of the tumour, that is, increases in hepatic 
citrate, spleen hypertrophy, thymic atrophy and in­
creases in epididymal fat pad weight.
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(v) Virology Studies
Oiiashi (1961) v/as able to isolate "toxohormone" 
from the spleens of mice infected v/ith Friend virus, 
suggesting that the possibility of viral infection 
showing a "toxohormone'-like activity must not be over­
looked. Kampschmidt and Schultz (1963) showed that the 
effects of tumour extracts on plasma iron (which is more 
sensitive to the effects of "toxohormone" than liver 
catalase) can be attributed to lipopolysaccharide from 
bacterial contaminants in the tumour. Kampschmidt 
and Schultz (I963) investigated several different 
transplantable tumours and found that in none of these 
could a "toxohormone" factor be isolated in the absence 
of bacteria. They did not discount, however, the 
possibility of viral contamination of these tumours being 
involved in producing a "toxohormone"-like effect.
Moreover, Davis, Gross and Lapis (1962) presented 
evidence that anaemia associated with the NK/LY ascites 
tumour in mice is caused by a replicating agent viroid 
in nature, which can be isolated from the tumour cellSo 
One virus particularly associated with murine tumours 
is LDV.
Since the initial report on the association of LDV 
with mouse tumours (Riley, Lilly, Huerto and Bardell, 
i960) a large number of experimental mouse tumours were 
found to be contaminated with this virus (Notkins, 1965). 
LDV was first recognized by its ability to increase 
nlasma LDK, It then became apparent that a number of
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other enzymes were elevated in the plasma of infected 
mice. These enzymes, included isocitrate dehydrogenase 
and malate dehydrogenase (Notkins, Greenfields, Marshall 
and Bane, 1963; Plagemann, Gregory, Swim and Chan,
1963). The effect of LDV on the activity of glycolytic 
enzymes- of infected mice, and the widespread 
contamination of muring tumours with this agent led to 
the consideration of the possibility that the TLX-5 
lymphoma used in this study might be contaminated with 
this virus. If this was the case, then the 
interpretation of experimental results would be 
difficult since LDV, as well as causing splenomegaly 
(Notkins, 1965) may also be causing the observed in­
crease in hepatic citrate levels of tumour-bearing mice, 
and mice treated with cell-free preparations of the 
tumour.
However, tumours can be freed from LDV contamination 
by passage through rats or by several passages through 
tissue culture (Notkins, 1965). In the absence of a 
specific serological test for LDV, the characteristic 
elevation of plasma or serum LDH activity, reaching 
a peak 96 hours after infection and the high virus 
titre 24 hours after infection, are sufficiently unique 
to determine whether LDV is present (Pope and Rowe,
1964).
Although there, have been reports of a close 
correlation between the growth of certain murine tumours 
and increases in plasma LDH (Hsieh, Suntzeff and Gowdr^r, 
1955; Manso, Sugiura and Wroblewski, 1956) these
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experiments had been,performed before it was recognized 
that many tumours were contaminated with LDV. Various 
workers then reinvestigated the relationship between 
tumour growth and plasma enzyme elevation in the presence 
and absence of LDV (Adams, Rowson and Sal am an, 1961; 
Notkins and Greenfield, 1962; Notkins, Greenfield, 
Marshall and Bane, 1963; Plagemann, Watanabe and Swim, 
1962; Riley, 1963; Yaffe, 1962). They showed that the 
early rise in plasma enzyme activity was due, not to the 
presence of a tumour, but to the presence of IDV, These 
reports indicated, however, that in the absence of LDV 
the activity of LDH, MDH and isocitrate dehydrogenase in 
turnour-bearing animals remained within the normal range 
until the tumours became palpable and then enzyme 
elevation roughly paralleled the growth of the tumour.
The problem of the possible contamination of TLX-5 
lymphoma with LDV was approached in the following ways;-
(1) SNl was extensively centrifuged to give a virus free 
preparation, SN2 (Notkins, 1965).
(2) TLX-5 lymphoma cells were passaged in tissue culture 
to remove endogenous virus contamination (Notkins, 
1965).
(3) Serum LDH activity was measured in tumour-bearing 
mice and mice injected with SN2,
(4) Tumour cells gro’wn in vitro and in vivo were 
examined by electron microscopy for the presence of 
viras particles.
Extensive centrifugation of SNl did not adversely 
affect its biological activity, and increases in hepatic
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citrate content were-observed•in mice treated with the 
virus free tumour preparation, SN2. TLX-5 lymphoma 
cells grown in vivo for several passages were also 
shown to significantly increase hepatic citrate levels.
However, the serum LDH activity of mice injected 
with in vivo grown TLX-5 cells was significantly 
increased, as was LDH activity in the serum of mice 
injected with SH2. Since the TLX-5 lymphoma is a 
particularly fast growing tumour, and since serum LDH 
activity was measured 96 hours after the injection of 
tumour cells or SN2, it is possible that a factor 
present in the tumour cell preparation and in SN2, which 
is not a virus-, is involved in producing this effect. 
Also, since red blood cells contain high levels of LDH, 
the slightest degree of haemolysis in the collected 
serum would increase LDH activity measured. Much more 
work is required before this phenomenon can be clearly 
understood.
Electron microscope examination by Notkins (1965) 
of a thin section of an osmium fixed pellet prepared 
from viremic plasma revealed rounded particles averaging 
40 mu in diameter, and elliptical or oblong particles 
56-40 mu wide and 45-75 mu long. These particles had 
a prominent, ring-shaped nucleoid 26-29 mu in diameter, 
consisting of a dense ring with an electron luscent 
core. Around the nucleoid was a 5-7 mu thick layer, 
limited by what appeared to be a thin outer membrane, 
Notkins (1965) also observed particles similar in size
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and shape within macrophages obtained from the 
peritoneal cavity of infected mice.
Electron microscope examination of in vivo grown 
TLX-5 lymphoma cells revealed the presence of particles 
in the preparation. These particles had an average 
length of 74- mu, and were not present in in vitro grown 
tumour cells. It is therefore possible that these 
virus particles are LDV particles, but further 
characterisation is required before they can be 
positively identified.
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C O N C L U S I O N S
This work has demonstrated the presence of a factor 
in the ascitic fluid of TLX-5 lymphoma bearing mice capable 
of increasing hepatic citrate levels. This factor is 
present in the serum of tumour bearing mice and is 
probably of tumour origin. It is non-dialysable, heat- 
labile, and protein in nature since treatment with trypsin 
destroys its biological activity, G-el filtration and gel 
electrophoresis experiments indicate that the factor has a 
molecular weight between 6,800-7,600 daltons.
Although in vivo grown TLX-5 lymphoma cells are 
contaminated with a virus, this factor does not appear to 
be a virus since it is present in SN2, and in vitro grown 
tumour cells which are free from viral contamination 
also bring about increases in hepatic citrate levels.
Moreover, a factor present in SN2 and therefore not a 
virus is active in increasing serum LLH activity in mice 
injected with SN2. The injection of SN2 into normal mice 
also brings about increases in the spleen weight of these 
mice. This factor involved in increasing spleen weight 
is non-dialysable, and heat-labile, with a molecular 
weight which is probably in the region 10,000-4-5,500 
daltons.
Although SI'Tl treatment increases the weight of mouse 
epididymal fat pads, dialysis, heat-treatment and 
ultracentrifugation of SNl destroy this effect. Results 
indicate that there are several different factors present 
in the ascitic fluid from turnour-bearing mice responsible 
for bringing about these observed systemic effects of the 
tumour.
Gel electrophoresis of this purified factor obtained 
from gel-filtration experiments was not conclusive in 
determining the homogeneity of the purified preparation, 
Further work using gels with a higher acrylamide 
concentration might be conclusive in determining this. 
Injection of mice with insulin was ineffective in 
increasing hepatic citrate levels, therefore this factor 
Was not insulin.
No attempt has been made in this work to study the 
mechanisms underlying the metabolic abnormalities produced 
by this biologically active component from TLX-5 lymphoma 
cells, and further work would be required to investigate 
the mechanisms involved.
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